



US 20210363213A1

(19) **United States**(12) **Patent Application Publication**
JUST et al.(10) **Pub. No.: US 2021/0363213 A1**(43) **Pub. Date: Nov. 25, 2021**(54) **GLUCAGON-GLP-1-GIP TRIPLE AGONIST
COMPOUNDS**May 5, 2016, now Pat. No. 10,131,702, filed as
application No. PCT/EP2014/073971 on Nov. 6,
2014.(71) Applicant: **Zealand Pharma A/S**, Soborg (DK)(60) Provisional application No. 61/900,933, filed on Nov.
6, 2013.(72) Inventors: **Rasmus JUST**, Copenhagen (DK);
Ditte RIBER, Brønshøj (DK); **Anne
Pernille Tofteng SHELTON**, Valby
(DK); **Torben ØSTERLUND**, Lund
(SE); **Kate HANSEN**, Copenhagen NV
(DK); **Lene JESSEN**, Glostrup (DK)**Publication Classification**(51) **Int. Cl.**
C07K 14/605 (2006.01)(52) **U.S. Cl.**
CPC **C07K 14/605** (2013.01); **A61K 38/00**
(2013.01)(21) Appl. No.: **17/388,328**(22) Filed: **Jul. 29, 2021****Related U.S. Application Data**(63) Continuation of application No. 16/151,603, filed on
Oct. 4, 2018, now Pat. No. 11,111,285, which is a
continuation of application No. 15/034,784, filed on(57) **ABSTRACT**The present invention relates to compounds which have
agonist activity at the glucagon, GIP and GLP-1 receptors,
and to their use in the treatment of metabolic disorders.**Specification includes a Sequence Listing.**

GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS

SEQUENCE LISTING

[0001] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 29, 2021 is named 50412-096003_Sequence_Listing_07_29_21_ST25 and is 73,649 bytes in size.

FIELD OF THE INVENTION

[0002] The invention relates to compounds having agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.

BACKGROUND OF THE INVENTION

[0003] Diabetes and obesity are increasing health problems globally and are associated with various other diseases, particularly cardiovascular diseases (CVD), obstructive sleep apnea, stroke, peripheral artery disease, microvascular complications and osteoarthritis. There are 246 million people worldwide with diabetes, and by 2025 it is estimated that 380 million will have diabetes. Many have additional cardiovascular risk factors including high/aberrant LDL and triglycerides and low HDL. Cardiovascular disease accounts for about 50% of the mortality in people with diabetes, and the morbidity and mortality rates relating to obesity and diabetes underscore the medical need for efficacious treatment options.

[0004] Pre-proglucagon is a 158 amino acid precursor polypeptide that is processed in different tissues to form a number of different proglucagon-derived peptides, including glucagon, glucagon-like peptide-1 (GLP-1 or GLP1), glucagon-like peptide-2 (GLP-2) and oxyntomodulin (OXM), which are involved in a wide variety of physiological functions, including glucose homeostasis, insulin secretion, gastric emptying, and intestinal growth, as well as the regulation of food intake. Glucagon is a 29-amino acid peptide that corresponds to amino acids 33 through 61 of pre-proglucagon, while GLP-1 is produced as a 37-amino acid peptide that corresponds to amino acids 72 through 108 of pre-proglucagon.

[0005] When blood glucose begins to fall, glucagon, a hormone produced by the pancreas, signals the liver to break down glycogen and release glucose, causing blood glucose levels to rise toward a normal level. In addition to controlling glucose homeostasis, glucagon reduces body weight probably through inhibition of food intake and stimulation of energy expenditure and/or lipolysis. GLP-1 has different biological activities compared to glucagon. Its actions include stimulation of insulin synthesis and secretion, inhibition of glucagon secretion, and inhibition of food intake. GLP-1 has been shown to reduce hyperglycemia (elevated glucose levels) in diabetic patients.

[0006] Exendin-4, a peptide from lizard venom that shares about 50% amino acid identity with GLP-1, activates the GLP-1 receptor and likewise has been shown to reduce hyperglycemia in diabetic patients.

[0007] Glucose-dependent insulintropic polypeptide (GIP) is a 42-amino acid gastrointestinal regulatory peptide that, like GLP-1, stimulates insulin secretion from pancreatic β (beta) cells in the presence of elevated blood glucose

levels. It is derived by proteolytic processing from a 133-amino acid precursor, preproGIP.

[0008] Interestingly, novel glucagon-GLP-1 dual acting receptor agonists are currently in pre-clinical development (see, e.g., WO2011/006497). In comparison to GLP-1 analogues, glucagon-GLP-1 dual agonists are associated with more profound and sustained body weight loss in animal models on top of the improvements in glycemic control. Thus, glucagon based drugs may have promise for the treatment of type 2 diabetes mellitus and/or obesity.

[0009] Incretins are gastrointestinal hormones that regulate blood glucose by enhancing glucose-stimulated insulin secretion (Drucker, D J and Nauck, M A, *Lancet* 368: 1696-705 (2006)). Two of the above mentioned peptides are known as incretins: GLP-1 and GIP. The discovery of the incretins has led to the development of two new classes of drugs for the treatment of diabetes mellitus. Thus, injectable GLP-1 receptor agonists, and small molecule compounds (oral DPP-4 inhibitors) that inhibit enzymatic inactivation of both endogenous GLP-1 and GIP, are now on the market (GLP-1 receptor agonists: Byetta™, Bydureon™ Lixisenatide™ and Liraglutide™, and DPP-4 inhibitors: Januvia™ Galvus™ Onglyza™ and Trajenta™). Apart from the acute effects of GLP-1 and GIP on insulin secretion, the two peptides also have long term effects. Evidence from several labs indicates that GLP-1 R agonists protect pancreatic β -cells by inhibiting apoptosis and enhancing proliferation. For instance, the study by Farilla et al. showed that GLP-1 had anti-apoptotic effects in human islets (Farilla, L, *Endocrinology* 144: 5149-58 (2003)). Such effects have not been reported for GIP until recently. In 2010, Weidenmaier et al. reported that a DPP-4 resistant GIP analogue has anti-apoptotic effects (Weidenmaier, S D, *PLOS One* 5(3): e9590 (2010)). Interestingly, in a mice model of diabetes and obesity the combination of the GLP-1 receptor agonist Liraglutide and an acylated GIP analogue show superior effects compared to treatment with Liraglutide or GIP analogue alone (Gault, V A, *Clinical Science* 121: 107-117 (2011)).

[0010] Chronic treatment with the GLP-1 receptor agonists causes significant weight loss in diabetic humans. Interestingly, extended use of DPP-4 inhibitors in similar patients does not consistently change body weight. Evidence suggests (Matthias Tschöp oral presentation at ADA (American Diabetes Association), 2011) that body weight loss associated with GLP-1 agonist treatment is enhanced when GLP-1 and GIP are co-administered. In rodents, co-administration of GLP-1 and GIP results in greater body weight loss than GLP-1 treatment alone (Finan, *Sci Transl Med.* 2013; 5(209):209ra151. Irwin N et al, 2009, *Regul Pept*; 153: 70-76. Gault et al, 2011, *Clin Sci*; 121:107-117). Thus, in addition to improving blood glucose, GIP may also enhance GLP-1-mediated body weight loss. In the same presentation it was also shown that combining glucagon, GLP-1 and GIP receptor agonism led to further body weight loss in DIO mice.

[0011] By combining glucagon, GLP-1 and GIP receptor agonism in novel inventive peptides it is anticipated that superior glycemic control and body weight loss can be achieved. Such peptides are likely to have strong incretin actions and improved β -cell preservation from the GLP-1 and GIP components, and have improved body weight loss from all three components by stimulating energy expenditure, lipolysis and reducing food intake.

SUMMARY OF THE INVENTION

[0012] Broadly, the present invention concerns Glucagon-GLP-1-GIP triple agonists (referred to in this specification as “triple agonists”) which comprise one or more substitutions as compared to wild-type glucagon and which may have the property of an altered, preferably increased GIP and GLP-1 receptor activity, e.g. as assessed in in vitro efficacy assays. In the present invention it has been found that Glucagon-GLP-1-GIP triple acting receptor agonists are superior to existing and marketed GLP-1 analogues because the triple agonists offer improved glycemic control, possible islet and β -cell preservation and enhanced body weight loss. The Glucagon-GLP-1-GIP triple agonists could be used as therapeutics for both type 2 diabetes mellitus, obesity and related disorders.

[0013] The invention provides a triple agonist having the general formula I:

(I)
(SEQ ID NO: 52)
R¹-Tyr-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-
X13-Leu-X15-X16-X17-Ala-X19-X20-X21-Phe-X23-X24-
Trp-Leu-X27-X28-X29-X30-Y1-R²

[0014] wherein

[0015] R¹ is H— (i.e., hydrogen), C₁₋₄ alkyl, acetyl, formyl, benzoyl, trifluoroacetyl or pGlu;

[0016] X2 is Aib, Gly, Ala, D-Ala, Ser, N-Me-Ser, Ac3c, Ac4c or Ac5c;

[0017] X10 is Tyr or Leu;

[0018] X12 is Lys, Ile or ψ ;

[0019] X13 is Ala, Tyr or Aib;

[0020] X15 is Asp or Glu;

[0021] X16 is Ser, Glu, Lys or ψ ;

[0022] X17 is Lys or ψ

[0023] X19 is Gln or Ala;

[0024] X20 is Lys, His, Arg or ψ ;

[0025] X21 is Ala, Asp or Glu;

[0026] X23 is Val or Ile;

[0027] X24 is Asn, Glu or ψ ;

[0028] X27 is Leu, Glu or Val;

[0029] X28 is Ala, Ser, Arg or ψ ;

[0030] X29 is Aib, Ala, Gln or Lys;

[0031] X30 is Lys, Gly, or is absent;

Y1 is

(SEQ ID NO: 53)
Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser,

(SEQ ID NO: 54)
Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser,

(SEQ ID NO: 55)
Lys-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser,

(SEQ ID NO: 56)
Lys-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser,

(SEQ ID NO: 57)
Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser
or

(SEQ ID NO: 58)
Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser,

-continued

or

is absent;

[0032] ψ is a residue of Lys, Arg, Orn or Cys in which the side chain is conjugated to a lipophilic substituent;

[0033] and

[0034] R² is —NH₂ or —OH;

[0035] or a pharmaceutically acceptable salt or solvate thereof.

[0036] In some embodiments, ψ is present at one of positions X12, X16 and X17.

[0037] In some embodiments, the compound contains only one residue ψ , which may be present at any one of positions X12, X16, X17, X20, X24 or X28. For example, it may be present at one of X12, X16 and X17.

[0038] In some embodiments, the compound may possess one or more of the following sets of residues:

[0039] K12 and Y13; I12 and Y13; K12 and A13; I12 and A13; or ψ 12 and Y13;

[0040] D15 and S16; D15 and E16; E15 and K16; D15 and ψ 16; E15 and S16; or E15 and ψ 16;

[0041] A19, H20, and D21; A19, K20, and D21; A19, R20, and D21; Q19, K20, and E21; A19, K20, and E21; or Q19, R20, and A21; but especially A19, H20, and D21; A19, R20, and D21 or Q19, R20, and A21;

[0042] I23 and E24; V23 and E24; or V23 and N24;

[0043] L27, R28, and A29; L27, S28, and A29; L27, A28, and Q29; E27, S28, and A29; or V27, and A28, and Aib29;

[0044] E15 and K17;

[0045] E15 and ψ 17;

[0046] E15 and ψ 17 and Q19;

[0047] Q19 and E24;

[0048] E16 and ψ 17 and Q19; and/or

[0049] K16 and ψ 17 and Q19.

[0050] Any one of these sets of residues, or combinations thereof, may be combined with:

[0051] Aib2, Ser2 or Ac4c2, especially Aib2; and/or

[0052] Tyr10 or Leu10, especially Tyr10.

[0053] Positions 1 to 29 may have the sequence

(SEQ ID NO: 1)
YSQGTFTSDYSKYLDSCAAHDFVEWLLRA;

(SEQ ID NO: 59)
YSQGTFTSDSKYLDSCAAHDFVEWLLRA;

(SEQ ID NO: 5)
Y-Aib-QGTFTSDYSIYLDSCAAHDFVEWLLSA;

(SEQ ID NO: 9)
Y-Aib-QGTFTSDYSIYLDSCAAHDFVEWLLSA;

(SEQ ID NO: 14)
Y-Aib-QGTFTSDYSIYLEKKAHDFVEWLLSA;

(SEQ ID NO: 17)
Y-Aib-QGTFTSDYSIYLESKAHDFVEWLLSA;

(SEQ ID NO: 18)
Y-Aib-QGTFTSDYSIYLDKKAHDFVEWLLSA;

(SEQ ID NO: 60)
Y-Aib-QGTFTSDYSIYLDSCAAHDFVEWLLSA;

(SEQ ID NO: 61)
Y-Aib-QGTFTSDYSIYLDSCAAHDFVEWLLSA;

-continued

(SEQ ID NO: 62)
Y-Aib-QGTFTSDYSKYLDSPA AHDFVEWLLSA;

(SEQ ID NO: 7)
Y-Aib-QGTFTSDYSKALDSKAAHDFVEWLLSA;

(SEQ ID NO: 8)
Y-Aib-QGTFTSDYSKYLESKAAHDFVEWLLSA;

(SEQ ID NO: 10)
Y-Aib-QGTFTSDYSIYLD SKAAKDFVEWLLSA;

(SEQ ID NO: 16)
Y-Aib-QGTFTSDYSIYLD EKAAKDFVEWLLSA;

(SEQ ID NO: 6)
Y-Aib-QGTFTSDYSKYLD SKAARDVEWLLSA;

(SEQ ID NO: 15)
Y-Aib-QGTFTSDYSIYLEKKAQKEFVEWLLSA;

(SEQ ID NO: 21)
Y-Aib-QGTFTSDYSKYLEKKAQKEFVEWLLSA;

(SEQ ID NO: 19)
Y-Aib-QGTFTSDYSIYLEKKAKEFVEWLLSA;

(SEQ ID NO: 20)
Y-Aib-QGTFTSDYSKALDEKAAKEFVEWLLSA;

(SEQ ID NO: 63)
Y-Aib-QGTFTSDYSIYLEKSPA AKEFVEWLLSA;

(SEQ ID NO: 64)
Y-Aib-QGTFTSDYSIYLESPA AKEFVEWLLSA;

(SEQ ID NO: 65)
Y-Aib-QGTFTSDYSYLYLEKKAKEFVEWLLSA;

(SEQ ID NO: 11)
Y-Aib-QGTFTSDYSIYLD SKAAHDFVNWLLSA;

(SEQ ID NO: 110)
Y-Aib-QGTFTSDLSIALEKSPA QRA FVEWLLAQ;

(SEQ ID NO: 67)
Y-Aib-QGTFTSDYSKYLD SPA AKDFIEWLESA;

(SEQ ID NO: 68)
Y-Aib-QGTFTSDYSIYLD SPA AKDFIEWLESA;

-continued

(SEQ ID NO: 69)
Y-Aib-QGTFTSDYSIYLD SPA AKDFIEWLESA;

(SEQ ID NO: 70)
Y-Aib-QGTFTSDYSIYLD SPA AKEFIEWLESA;

(SEQ ID NO: 3)
Y-Aib-QGTFTSDYSKYLD SKAAHDFVEWLLRA;

(SEQ ID NO: 12)
Y-Aib-QGTFTSDYSIYLD SKAAHDFVEWLLRA;

(SEQ ID NO: 71)
Y-Aib-QGTFTSDYSIYLD SPA AHDFVEWLLRA;

(SEQ ID NO: 72)
Y-Aib-QGTFTSDYSIYLEKSPA QRA FVEWLLRA;

(SEQ ID NO: 73)
Y-Aib-QGTFTSDYSIALDKSPA QRA FVNWLLVA-Aib;

(SEQ ID NO: 74)
Y-Ac4c-QGTFTSDYSIYLD SPA AKEFIEWLESA;

(SEQ ID NO: 75)
Y-Ac4c-QGTFTSDYSIALEKSPA QRA FVEWLLAQ;
or

(SEQ ID NO: 76)
Y-Ac4c-QGTFTSDYSIYLD KSPA QRA FVEWLLAQ.

[0054] Alternatively, positions 1 to 29 may differ at up to 4 positions, e.g. at 1, 2, 3 or 4 positions, from any of the specific sequences shown above, within the constraints of Formula I.

[0055] For example, positions 1 to 29 may differ at up to 4 positions, e.g. at 1, 2, 3 or 4 positions from one of the following sequences:

(SEQ ID NO: 63)
Y-Aib-QGTFTSDYSIYLEKSPA AKEFVEWLLSA;

(SEQ ID NO: 60)
Y-Aib-QGTFTSDYSIYLD SPA AHDFVEWLLSA;
or

(SEQ ID NO: 77)
Y-Aib-QGTFTSDYSIALEKSPA QRA FVEWLLAQ.

[0056] Positions 1 to 29 may have the sequence:

(SEQ ID NO: 4)
YSQGTFTSDYSKYLD-K (Hexadecanoyl-isoGlu) -KAAHDFVEWLLRA;

(SEQ ID NO: 27)
Y-Aib-QGTFTSDYSIYLD E-K (Hexadecanoyl-isoGlu) -AAHDFVEWLLSA;

(SEQ ID NO: 85)
Y-Aib-QGTFTSDYSIYLD S-K (Hexadecanoyl-isoGlu) -AAHDFVEWLLSA;

(SEQ ID NO: 2)
Y-Aib-QGTFTSDYSKYLD S-K (Hexadecanoyl-isoGlu) -AAHDFVEWLLSA;

(SEQ ID NO: 22)
Y-Aib-QGTFTSDYSIYLEK-K (Hexadecanoyl-isoGlu) -AAKEFVEWLLSA;

(SEQ ID NO: 23)
Y-Aib-QGTFTSDYSIYLE-K (Hexadecanoyl-isoGlu) -KAAKEFVEWLLSA;

(SEQ ID NO: 24)
Y-Aib-QGTFTSDYS-K (Hexadecanoyl-isoGlu) -YLEKKAKEFVEWLLSA;

-continued

(SEQ ID NO: 22)
Y-Aib-QGTFTSDYSIYLEK-K(Hexadecanoyl-isoGlu)-AAKEFVEWLLSA;

(SEQ ID NO: 86)
Y-Aib-QGTFTSDYSIYLEK-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AAKEFVEWLLSA;

(SEQ ID NO: 87)
Y-Aib-QGTFTSDYSIYLEK-K([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)-
AAKEFVEWLLSA;

(SEQ ID NO: 88)
Y-Aib-QGTFTSDYSIYLDK-K([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)-
AQRAFVEWLLAQ;

(SEQ ID NO: 89)
Y-Aib-QGTFTSDYSIYLDK-K([17-carboxy-heptadecanoyl]-isoGlu)-
AQRAFVEWLLAQ;

(SEQ ID NO: 90)
Y-Aib-QGTFTSDYSIYLDK-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQ;

(SEQ ID NO: 91)
Y-Aib-QGTFTSDYSIYLDK-K(eicosanoyl-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQ;

(SEQ ID NO: 92)
Y-Aib-QGTFTSDYSIALEK-K([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)-
AQRAFVEWLLAQ;

(SEQ ID NO: 93)
Y-Aib-QGTFTSDYSIALEK-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQ;

(SEQ ID NO: 94)
Y-Aib-QGTFTSDYSIALEK-K([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)-
AQRAFVEWLLAQ;

(SEQ ID NO: 95)
Y-Aib-QGTFTSDLSIALEK-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQ;

(SEQ ID NO: 25)
Y-Aib-QGTFTSDYSIYLDK-K(Hexadecanoyl-isoGlu)-AAKDFIEWLESA;

(SEQ ID NO: 29)
Y-Aib-QGTFTSDYSIYLDK-K(Hexadecanoyl-isoGlu)-AAKDFIEWLESA;

(SEQ ID NO: 30)
Y-Aib-QGTFTSDYSIYLDK-K(Hexadecanoyl-isoGlu)-AAKDFIEWLESA;

(SEQ ID NO: 38)
Y-Aib-QGTFTSDYSIYLDK-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AAKEFIEWLESA;

(SEQ ID NO: 39)
Y-Aib-QGTFTSDYSIYLDK-K([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)-
AAKEFIEWLESA;

(SEQ ID NO: 26)
Y-Aib-QGTFTSDYSIYLDK-K(Hexadecanoyl-isoGlu)-AAHDFVEWLLRA;

(SEQ ID NO: 96)
Y-Aib-QGTFTSDYSIYLEK-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AQRAFVEWLLRA;

(SEQ ID NO: 97)
Y-Aib-QGTFTSDYSIYLEK-K([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)-
AQRAFVEWLLRA;

(SEQ ID NO: 98)
Y-Aib-QGTFTSDYSIALD-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AQRAFVNWLVA-Aib;

(SEQ ID NO: 99)
Y-Aib-QGTFTSDYSIALD-K(Octadecanoyl-Dapa-Peg3-Peg3)-AQRAFVNWLVA-Aib;

-continued

(SEQ ID NO: 100)
Y-Aib-QGTFTSDYSIALDK-K([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3) -
AQRAFVNWLVA-Aib;

(SEQ ID NO: 40)
Y-Ac4c-QGTFTSDYSIYLDE-K([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3) -
AAKEFIEWLESA;

(SEQ ID NO: 101)
Y-Ac4c-QGTFTSDYSIALE-K([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3) -
AQRAFVEWLLAQ;
or

(SEQ ID NO: 102)
Y-Ac4c-QGTFTSDYSIYLDK-K(19-carboxy-heptadecanoyl-isoGlu-Peg3-Peg3) -
AQRAFVEWLLAQ.

[0057] The peptide backbone of Formula I may have the sequence:

-continued

		Y-Aib-QGTFTSDYSKYLEKKAQKEFVEWLLSA;	(SEQ ID NO: 21)
	(SEQ ID NO: 1)		(SEQ ID NO: 19)
YSQGTFTSDYSKYLDSKAAHDFVEWLLRA;		Y-Aib-QGTFTSDYSIYLEKKAQKEFVEWLLSA;	
	(SEQ ID NO: 59)		(SEQ ID NO: 20)
YSQGTFTSDYSKYLDΨKAAHDFVEWLLRA;		Y-Aib-QGTFTSDYSKALDEKAAKEFVEWLLSA;	
	(SEQ ID NO: 5)		(SEQ ID NO: 63)
Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;		Y-Aib-QGTFTSDYSIYLEKΨAAKEFVEWLLSA;	
	(SEQ ID NO: 9)		(SEQ ID NO: 64)
Y-Aib-QGTFTSDYSIYLDEKAAHDFVEWLLSA;		Y-Aib-QGTFTSDYSIYLEΨKAAKEFVEWLLSA;	
	(SEQ ID NO: 13)		(SEQ ID NO: 65)
Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSAGPSSGAPPPS;		Y-Aib-QGTFTSDYSΨYLEKKAQKEFVEWLLSA;	
	(SEQ ID NO: 14)		(SEQ ID NO: 79)
Y-Aib-QGTFTSDYSIYLEKKAHDFVEWLLSA;		Y-Aib-QGTFTSDYSIYLEKΨAAKEFVEWLLSAGPSSGAPPPS;	
	(SEQ ID NO: 17)		(SEQ ID NO: 11)
Y-Aib-QGTFTSDYSIYLESKAAHDFVEWLLSA;		Y-Aib-QGTFTSDYSIYLDKAAHDFVNWLLSA;	
	(SEQ ID NO: 18)		(SEQ ID NO: 80)
Y-Aib-QGTFTSDYSIYLDKKAHDFVEWLLSA;		Y-Aib-QGTFTSDYSIYLDKΨAQRAFVEWLLAQGPSSGAPPPS;	
	(SEQ ID NO: 60)		(SEQ ID NO: 81)
Y-Aib-QGTFTSDYSIYLDEΨAAHDFVEWLLSA;		Y-Aib-QGTFTSDYSIALEKΨAQRAFVEWLLAQK;	
	(SEQ ID NO: 78)		(SEQ ID NO: 66)
Y-Aib-QGTFTSDYSIYLDKΨAAHDFVEWLLSAGPSSGAPPPS;		Y-Aib-QGTFTSDLSIALEKΨAQRAFVEWLLAQK;	
	(SEQ ID NO: 62)		(SEQ ID NO: 67)
Y-Aib-QGTFTSDYSKYLDKΨAAHDFVEWLLSA;		Y-Aib-QGTFTSDYSKYLDKΨAAKDFIEWLESA;	
	(SEQ ID NO: 7)		(SEQ ID NO: 68)
Y-Aib-QGTFTSDYSKALDSKAAHDFVEWLLSA;		Y-Aib-QGTFTSDYSIYLDEΨAAKDFVEWLESA;	
	(SEQ ID NO: 8)		(SEQ ID NO: 69)
Y-Aib-QGTFTSDYSKYLESKAAHDFVEWLLSA;		Y-Aib-QGTFTSDYSIYLDEΨAAKDFIEWLESA;	
	(SEQ ID NO: 10)		(SEQ ID NO: 70)
Y-Aib-QGTFTSDYSIYLDKAAKDFVEWLLSA;		Y-Aib-QGTFTSDYSIYLDEΨAAKEFIEWLESA;	
	(SEQ ID NO: 16)		(SEQ ID NO: 3)
Y-Aib-QGTFTSDYSIYLDEKAAKDFVEWLLSA;		Y-Aib-QGTFTSDYSKYLDKAAHDFVEWLLRA;	
	(SEQ ID NO: 6)		(SEQ ID NO: 12)
Y-Aib-QGTFTSDYSKYLDKAAHDFVEWLLSA;		Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLRA;	
	(SEQ ID NO: 15)		

-continued

(SEQ ID NO: 71)
Y-Aib-QGTFTSDYSIYLDSPA AHDFVEWLLRA;
(SEQ ID NO: 72)
Y-Aib-QGTFTSDYSIYLEKSPA QRA FVEWLLRA;
(SEQ ID NO: 82)
Y-Aib-QGTFTSDYSIALDKSPA QRA FVNWLV A-Aib-KPSSGAPPPS;
(SEQ ID NO: 74)
Y-Ac4c-QGTFTSDYSIYLDESPA AKEFIEWLESA;
(SEQ ID NO: 83)
Y-Ac4c-QGTFTSDYSIALEKSPA QRA FVEWLLAQK;
[[Y]] or
(SEQ ID NO: 84)
Y-Ac4c-QGTFTSDYSIYLDKSPA QRA FVEWLLAQGPSSGAPPPS.

[0058] Alternatively, the peptide backbone sequence may differ at up to 5 positions from one of the sequences shown above, within the constraints of Formula I. For the avoidance of doubt, a sequence satisfying the definition of Y1 is regarded as a single position. Typically the compound differs from the reference sequence at only 4 positions in X1 to X29. Thus, if the compound differs from the reference sequence at 5 positions, one of those positions is generally X30 or Y1.

[0059] In particular, the peptide backbone sequence may differ at up to 5 positions from one of the sequences:

(SEQ ID NO: 79)
Y-Aib-QGTFTSDYSIYLEKSPA AKEFVEWLLSAGPSSGAPPPS;
(SEQ ID NO: 60)
Y-Aib-QGTFTSDYSIYLDESPA AHDFVEWLLSA;
or
(SEQ ID NO: 81)
Y-Aib-QGTFTSDYSIALEKSPA QRA FVEWLLAQK.

[0060] The peptide backbone of Formula I may have the sequence:

(SEQ ID NO: 4)
YSQGTFTSDYSKYLD-K(Hexadecanoyl-isoGlu)-
KAAHDFVEWLLRA;
(SEQ ID NO: 27)
Y-Aib-QGTFTSDYSIYLDE-K(Hexadecanoyl-isoGlu)-
AAHDFVEWLLSA;
(SEQ ID NO: 28)
Y-Aib-QGTFTSDYSIYLDK-K(Hexadecanoyl-isoGlu)-
AAHDFVEWLLSAGPSSGAPPPS;
(SEQ ID NO: 2)
Y-Aib-QGTFTSDYSKYLDK-K(Hexadecanoyl-isoGlu)-
AAHDFVEWLLSA;
(SEQ ID NO: 22)
Y-Aib-QGTFTSDYSIYLEK-K(Hexadecanoyl-isoGlu)-
AAKEFVEWLLSA;
(SEQ ID NO: 23)
Y-Aib-QGTFTSDYSIYLE-K(Hexadecanoyl-isoGlu)-
KAAKEFVEWLLSA;
(SEQ ID NO: 24)
Y-Aib-QGTFTSDYS-K(Hexadecanoyl-isoGlu)-
YLEKKAKEFVEWLLSA;

-continued

(SEQ ID NO: 103)
Y-Aib-QGTFTSDYSIYLEK-K(Hexadecanoyl-isoGlu)-
AAKEFVEWLLSAGPSSGAPPPS;
(SEQ ID NO: 36)
Y-Aib-QGTFTSDYSIYLEK-K(Octadecanoyl-isoGlu-Peg3-
Peg3)-AAKEFVEWLLSAGPSSGAPPPS;
(SEQ ID NO: 37)
Y-Aib-QGTFTSDYSIYLEK-K([17-carboxy-heptadecanoyl]-
isoGlu-Peg3-Peg3)-AAKEFVEWLLSAGPSSGAPPPS;
(SEQ ID NO: 32)
Y-Aib-QGTFTSDYSIYLDK-K([17-carboxy-heptadecanoyl]-
isoGlu-Peg3-Peg3)-AQRA FVEWLLAQGPSSGAPPPS;
(SEQ ID NO: 33)
Y-Aib-QGTFTSDYSIYLDK-K([17-carboxy-heptadecanoyl]-
isoGlu)-AQRA FVEWLLAQGPSSGAPPPS;
(SEQ ID NO: 34)
Y-Aib-QGTFTSDYSIYLDK-K(Octadecanoyl-isoGlu-Peg3-
Peg3)-AQRA FVEWLLAQGPSSGAPPPS;
(SEQ ID NO: 104)
Y-Aib-QGTFTSDYSIYLD-K(eicosanoyl-isoGlu-Peg3-Peg3)-
AQRA FVEWLLAQGPSSGAPPPS;
(SEQ ID NO: 44)
Y-Aib-QGTFTSDYSIALEK-K([17-carboxy-heptadecanoyl]-
isoGlu-Peg3-Peg3)-AQRA FVEWLLAQK;
(SEQ ID NO: 45)
Y-Aib-QGTFTSDYSIALEK-K(Octadecanoyl-isoGlu-Peg3-
Peg3)-AQRA FVEWLLAQK;
(SEQ ID NO: 105)
Y-Aib-QGTFTSDYSIALE-K([19-carboxy-nonadecanoyl]-
isoGlu-Peg3-Peg3)-AQRA FVEWLLAQK;
(SEQ ID NO: 106)
Y-Aib-QGTFTSDLSIALE-K(Octadecanoyl-isoGlu-Peg3-
Peg3)-AQRA FVEWLLAQK;
(SEQ ID NO: 25)
Y-Aib-QGTFTSDYSKYLDE-K(Hexadecanoyl-isoGlu)-
AAKDFIEWLESA;
(SEQ ID NO: 29)
Y-Aib-QGTFTSDYSIYLDE-K(Hexadecanoyl-isoGlu)-
AAKDFIEWLESA;
(SEQ ID NO: 30)
Y-Aib-QGTFTSDYSIYLDE-K(Hexadecanoyl-isoGlu)-
AAKDFIEWLESA;
(SEQ ID NO: 38)
Y-Aib-QGTFTSDYSIYLDE-K(Octadecanoyl-isoGlu-Peg3-
Peg3)-AAKEFIEWLESA;
(SEQ ID NO: 39)
Y-Aib-QGTFTSDYSIYLDE-K([17-carboxy-heptadecanoyl]-
isoGlu-Peg3-Peg3)-AAKEFIEWLESA;
(SEQ ID NO: 26)
Y-Aib-QGTFTSDYSIYLDK-K(Hexadecanoyl-isoGlu)-
AAHDFVEWLLRA;
(SEQ ID NO: 96)
Y-Aib-QGTFTSDYSIYLE-K(Octadecanoyl-isoGlu-Peg3-
Peg3)-AQRA FVEWLLRA;
(SEQ ID NO: 97)
Y-Aib-QGTFTSDYSIYLE-K([17-carboxy-heptadecanoyl]-
isoGlu-Peg3-Peg3)-AQRA FVEWLLRA;

-continued

(SEQ ID NO: 107)
Y-Aib-QGTFTSDYSIALD-K(Octadecanoyl-isoGlu-Peg3-
Peg3)-AQRAFNWLVA-Aib-KPSSGAPPPS;

(SEQ ID NO: 108)
Y-Aib-QGTFTSDYSIALD-K(Octadecanoyl-Dapa-Peg3-Peg3)-
AQRAFNWLVA-Aib-KPSSGAPPPS;

(SEQ ID NO: 43)
Y-Aib-QGTFTSDYSIALDK-K([19-carboxy-nonadecanoyl]-
isoGlu-Peg3-Peg3)-AQRAFNWLVA-Aib-KPSSGAPPPS;

(SEQ ID NO: 40)
Y-Ac4c-QGTFTSDYSIYLDE-K([19-carboxy-nonadecanoyl]-
isoGlu-Peg3-Peg3)-AAKEFIEWLESA;

(SEQ ID NO: 109)
Y-Ac4c-QGTFTSDYSIALE-K([19-carboxy-nonadecanoyl]-
isoGlu-Peg3-Peg3)-AQRAFVEWLLAQK;
or

(SEQ ID NO: 51)
Y-Ac4c-QGTFTSDYSIYLDK-K([19-carboxy-heptadecanoyl]-
isoGlu-Peg3-Peg3)-AQRAFVEWLLAQGPSSGAPPPS.

[0061] Certain of the Y1 groups, when present, may provide increased stability in vivo, e.g. in serum, and so may contribute to the half life of the GIP analogue. Without wishing to be bound by theory, it is believed that these groups may help to stabilize the three dimensional conformation of the molecule and/or provide resistance to proteolytic degradation.

[0062] For example, the Y1 sequences Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser (SEQ ID NO:53), Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser (SEQ ID NO: 54), Lys-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser (SEQ ID NO: 55), Lys-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser (SEQ ID NO: 56), Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser (SEQ ID NO: 57) and Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser (SEQ ID NO: 58) have homology with a C-terminal portion of the Exendin-4 molecule and appear to contribute to the stability of the molecule without concomitantly providing significant levels of GLP-1 agonist activity.

[0063] The invention further provides a nucleic acid encoding a peptide having the sequence X1-X30 of Formula I. Also provided is an expression construct (also known as an expression vector) comprising a nucleic acid of the invention in operable linkage with suitable regulatory elements to direct expression of the peptide, e.g. transcription and translation. The invention also provides a host cell comprising a nucleic acid or expression construct and capable of expressing, and optionally secreting, the peptide.

[0064] The peptide may itself be a compound of the invention, e.g. when the peptide contains only naturally occurring amino acids (i.e. proteinogenic amino acids), does not contain a residue ψ , and where R^1 and R^2 are H— and —OH respectively. Alternatively, the peptide may be a precursor of a compound of the invention.

[0065] The invention further provides a pharmaceutical composition comprising a triple agonist as described herein, or a pharmaceutically acceptable salt or solvate thereof, in admixture with a carrier, preferably a pharmaceutically acceptable carrier. The triple agonist may, for example, be a pharmaceutically acceptable acid addition salt.

[0066] The pharmaceutical composition may be formulated as a liquid suitable for administration by injection or infusion, or which is formulated to cause slow release of said triple agonist.

[0067] The invention further provides a therapeutic kit comprising a triple agonist as described herein, and a device comprising a triple agonist as described herein.

[0068] The invention further provides a triple agonist as described herein, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of medical treatment, e.g. for use in the treatment and/or prevention of a metabolic disorder.

[0069] The invention further provides the use of a triple agonist as described herein, or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medication for the treatment and/or prevention of a metabolic disorder.

[0070] The invention further provides a method of prevention and or/treatment of a metabolic disorder in a subject, comprising administering a triple agonist as described herein, or a pharmaceutically acceptable salt or solvate thereof, to the subject.

[0071] The metabolic disorder may be diabetes or a diabetes related disorder, or obesity or an obesity related disorder. The link between obesity and diabetes is well known, so these conditions are not necessarily separate or mutually exclusive.

[0072] Diabetes related disorders include insulin resistance, glucose intolerance, increased fasting glucose, pre-diabetes, type 1 diabetes, type 2 diabetes, gestational diabetes hypertension, dyslipidemia, bone related disorders and combinations thereof.

[0073] Diabetes related disorders also include atherosclerosis, arteriosclerosis, coronary heart disease, peripheral artery disease and stroke; or conditions associated with atherogenic dyslipidemia, blood fat disorders, elevated blood pressure, hypertension, a prothrombotic state and a proinflammatory state.

[0074] Bone related disorders include, but are not limited to osteoporosis and increased risk of bone fracture.

[0075] The blood fat disorder may be selected from high triglycerides, low HDL cholesterol, high LDL cholesterol, and plaque buildup in artery walls, or a combination thereof.

[0076] The prothrombotic state may be selected from high fibrinogen levels in the blood and high plasminogen activator inhibitor-1 levels in the blood.

[0077] The proinflammatory state may be an elevated C-reactive protein level in the blood.

[0078] Obesity related disorders include obesity linked inflammation, obesity linked gallbladder disease and obesity induced sleep apnea, or may be associated with a condition selected from atherogenic dyslipidemia, blood fat disorders, elevated blood pressure, hypertension, a prothrombotic state, and a proinflammatory state, or a combination thereof.

DETAILED DESCRIPTION OF THE INVENTION

[0079] Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of, chemistry, molecular biology, cell and cancer biology, immunology, microbiology,

pharmacology, and protein and nucleic acid chemistry, described herein, are those well known and commonly used in the art.

Definitions

[0080] Unless specified otherwise, the following definitions are provided for specific terms, which are used in the above written description.

[0081] Throughout this specification, the word “comprise” or variations such as “comprises” or “comprising” will be understood to imply the inclusion of a stated integer (or components) or group of integers (or components), but not the exclusion of any other integer (or components) or group of integers (or components).

[0082] The singular forms “a,” “an,” and “the” include the plurals unless the context clearly dictates otherwise.

[0083] The term “including” is used to mean “including but not limited to.” “Including” and “including but not limited to” are used interchangeably.

[0084] The terms “patient,” “subject,” and “individual” may be used interchangeably and refer to either a human or a non-human animal. These terms include mammals such as humans, primates, livestock animals (e.g., bovines, porcines), companion animals (e.g., canines, felines) and rodents (e.g., mice and rats).

[0085] The term “solvate” in the context of the present invention refers to a complex of defined stoichiometry formed between a solute (in casu, a peptide conjugate or pharmaceutically acceptable salt thereof according to the invention) and a solvent. The solvent in this connection may, for example, be water, ethanol or another pharmaceutically acceptable, typically small-molecular organic species, such as, but not limited to, acetic acid or lactic acid. When the solvent in question is water, such a solvate is normally referred to as a hydrate.

[0086] The term “agonist” as employed in the context of the invention refers to a substance (ligand) that activates the receptor type in question.

[0088] Among sequences disclosed herein are sequences incorporating an “H—” moiety at the amino terminus (N-terminus) of the sequence, and either an “—OH” moiety or an “—NH₂” moiety at the carboxy terminus (C-terminus) of the sequence. In such cases, and unless otherwise indicated, an “H—” moiety at the N-terminus of the sequence in question indicates a hydrogen atom (i.e. R¹=H—), corresponding to the presence of a free primary or secondary amino group at the N-terminus, while an “—OH” or an “—NH₂” moiety at the C-terminus of the sequence (i.e. R²=—OH or —NH₂) indicates a carboxy (—COOH) group or an amido (—CONH₂) group at the C-terminus, respectively.

[0089] Other R¹ groups are possible at the N-terminus, including pyroglutamic acid (pGlu; (S)-(-)-2-pyrrolidone-5-carboxylic acid), C₁₋₄ alkyl, acetyl, formyl, benzoyl and trifluoroacetyl.

[0090] Receptor Agonist Activity

[0091] As mentioned above, the compounds described herein are Glucagon-GIP-GLP 1 dual receptor agonists. That is to say, they have agonist activity at all three of the glucagon receptor, the GIP receptor and the GLP-1 receptor.

[0092] The term “agonist” as employed in the context of the invention refers to a substance (ligand) that is capable of binding to a particular receptor and activating signaling by that receptor. Thus a GIP receptor agonist is capable of binding to the GIP receptor (designated GIP-R) and activating signaling by that receptor, e.g. by generation of cAMP or inducing Ca²⁺ release.

[0093] Agonist activity at the GIP receptor may therefore be measured by assessing GIP receptor signalling, which may may, for example, be measured via cAMP production or Ca²⁺ release.

[0094] The cDNA sequence encoding the human GIP receptor has GenBank accession no. BC101673.1 (GI: 75516688). The encoded amino acid sequence (including signal peptide) is:

(SEQ ID NO: 111)

```

1  MTTSPILQLL LRLSLCGLLL QRAETGSKGQ TAGELYQRWE RYRRECQETL AAAPPPSGLA
61  CNGSFDMYVC WDYAAPNATA RASCPWYLPW HHHVAAGFVL RQCGSDGQWG LWRDHTQCEN
121  PEKNEAFLDQ RLILERLQVM YTVGYSLSLA TLLALLILS LFRRLLHCTRN YIHINLFTSF
181  MLRAAAILSR DRLLPRPGPY LGDQALALWN QALAAACRTAQ IVTQYCVGAN YTWLLVEGVY
241  LHSLLVLVGG SEEGHFRYYL LLGWGAPALF VIPWVIVRYL YENTQCWERN EVKAIWIIIR
301  TPILMTILIN FLIFIRILGI LLSKLRTRQM RCRDYRLRLA RSTLTIVPLL GVHEVVFAPV
361  TEEQARGALR FAKLGFEIFL SSFQGFLVSV LYCFINKEVQ SEIRRGWHHC RLRRSLGEEQ
421  RQLPERAFRA LPSSGSGPGEV PTSRGLSSGT LPGPGNEASR ELESYC
(GenBank AAI01674.1 GI: 75516689)". This may be employed in any assays
to determine GIP signalling.
```

[0087] Throughout the description and claims the conventional one-letter and three-letter codes for natural (or “proteinogenic”) amino acids are used, as well as generally accepted three letter codes for other (non-natural or “non-proteinogenic”) α-amino acids, such as Aib (α-aminoisobutyric acid), Orn (ornithine) and D-Ala (D-alanine). All amino acid residues in peptides of the invention are preferably of the L-configuration except where explicitly stated.

[0095] Similarly the compounds have agonist activity at the GLP-1 receptor (GLP-1-R), i.e. they are capable of binding to the GLP-1 receptor and activating signaling by that receptor, e.g. by generation of cAMP or inducing Ca²⁺ release. Agonist activity at the GLP-1 receptor may therefore be measured by assessing GLP-1 receptor signalling, which may may, for example, be measured via cAMP production or Ca²⁺ release.

[0096] The GLP-1 receptor may have the sequence of the human glucagon-like peptide 1 receptor (GLP-1 R) having primary accession number P43220. The precursor protein (including signal peptide) has primary accession number NP_002053.3; GI:166795283 and has sequence:

(SEQ ID NO: 112)

```

1  MAGAPGPLRL ALLLLGMVGR AGPRPQGATV SLWETVQKWR EYRRQCQRL TEDPPATDL
61  FCNRTFDEYA CWPDGEPSF VNVSCPWYLP WASSVPQGHV YRFCTAEGLW LQKDNSSLPW
121  RDLSECEESK RGERSSPEEQ LLFLYIIYTV GYALSFSALV IASAILLGFR HLHCTRNYIH
181  LNLFAFSLR ALSVFIKDA LKWMYSTAAQ QHQWDGLLSY QDSLSCRLVF LLMQYCVAAAN
241  YYWLLVEGVY LYTLAFAVSV SEQWIFRLYV SIGWGVPLLF VVPWGIVKYL YEDEGCWTRN
301  SNMNYWLIIR LPILFAIGN FLIFVRVICI VVSKLKANLM CKTDIKCRLA KSTLTLIPLL
361  GTHEVIFAFV MDEHARGTLR FIKLFTLSF TSFQGLMVAI LYCFVNNEVQ LEFRKSWERW
421  RLEHLHIQRD SSMKPLKCPT SSLSSGATAG SSMYTATCQA SCS.

```

[0097] Similarly the compounds have agonist activity at the glucagon receptor (Glu-R), i.e. they are capable of binding to the glucagon receptor and activating signaling by that receptor, e.g. by generation of cAMP or inducing Ca^{2+} release. Agonist activity at the glucagon receptor may therefore be measured by assessing glucagon receptor signalling, which may, for example, be measured via cAMP production or Ca^{2+} release.

[0098] The glucagon receptor may have the sequence of the human glucagon receptor (Glu-R) having primary accession number P47871. The precursor protein (including signal peptide) has primary accession number NP_000151.1; GI:4503947, and has the sequence:

(SEQ ID NO: 113)

```

1  MPPCQPQRPL LLLLLLLACQ PQVPSAQVMD FLFEKWKLYG DQCHNLSL PPPTLVCNR
61  TFDKYSCWPD TPANTTANIS CPWYLPWHHK VQHRFVFKRC GPDGQWVRGP RGQPWRDASQ
121  CQMDGEEIEV QKEVAKMYSS FQVMYTVGYS LSLGALLLAL AILGGLSKLH CTRNAIHANL
181  FASFVLKASS VLVIDGLLRT RYSQKIGDDL SVSTWLSDGA VAGCRVAADF MQYGIVANYC
241  WLLVEGLYLH NLLGLATLPE RSFFSLYLG I GWGAPMLFVV PWAUVKCLFE NVQCWTSNDN
301  MGFWWILRFP VFLAILINFF IFVRIVQLLV AKLRARQMHM TDYKFRLLAKS TLTLIPLLGV
361  HEVVFVAFVTD EHAQGTLSA KLFFDLFLSS FQGLLVAVLY CFLNKEVQSE LRRRWHRWRL
421  GKVLWEERNT SNHRASSSPG HGPPSKELQF GRGGGSDSS AETPLAGGLP RLAESPF

```

[0099] In all cases, where sequences of precursor proteins are referred to, it should of course be understood that assays may make use of the mature protein, lacking the signal sequence.

[0100] The compounds of the present invention have at least one GIP, one glucagon, and one GLP-1 biological activity, in particular in treatment of metabolic diseases such as diabetes and obesity. This can be assessed, e.g., in vivo assays, for example as described in the examples, in which the blood glucose level or another biological activity is determined after a test animal has been treated or exposed to a triple agonist. In particular, compounds of the invention may be capable of improving glycaemic control when

administered to a diabetic subject. Additionally or alternatively, they may be capable of reducing body weight when administered to an overweight or obese subject. In either case, the effect may be superior to that obtained with an equivalent quantity (by mass, or molar ratio) of wild type

human GIP or GLP-1 in comparable subjects when given according to a comparable dosing regime.

[0101] Activity in in vitro assays may also be used as a measure of the compounds' activity. Typically the compounds have activity at the glucagon, GLP-1 and GIP receptors (designated GCG-R, GLP-1-R and GIP-R respectively). EC_{50} values may be used as a numerical measure of agonist potency at a given receptor. An EC_{50} value is a measure of the concentration of a compound required to achieve half of that compound's maximal activity in a particular assay. Thus, for example, a compound having EC_{50} [GLP-1R] lower than the EC_{50} [GLP-1 R] of native GIP in a particular assay may be considered to have higher

potency at the GLP-1R than GIP. In some embodiments of the present invention, the EC_{50} GLP-1-R and/or EC_{50} GIP-R and/or EC_{50} GCG-R is below 1.0 nM, below 0.9 nM, below 0.8 nM, below 0.7 nM, below 0.6 nM, below 0.5 nM, below 0.4 nM, below 0.3 nM, below 0.2 nM, below 0.1 nM, below 0.09 nM, below 0.08 nM, below 0.07 nM, below 0.06 nM, below 0.05 nM, below 0.04 nM, below 0.03 nM, below 0.02 nM, below 0.01 nM, below 0.009 nM, below 0.008 nM, below 0.007 nM, below 0.006 nM, or below 0.005 nM, e.g. when assessed using the assay described in Example 2.

[0102] Lipophilic Group

[0103] The compound of the invention may comprise a residue ψ , i.e. a residue selected from Lys, Arg, Orn and Cys in which the side chain is conjugated to a lipophilic substituent.

[0104] Without wishing to be bound by any particular theory, it is thought that the substituent binds plasma proteins (e.g. albumin) in the blood stream, thus shielding the compounds of the invention from enzymatic degradation and renal clearance and thereby enhancing the half-life of the compounds. It may also modulate the potency of the compound, e.g. with respect to the GIP receptor, the glucagon receptor and/or the GLP-1 receptor.

[0105] The substituent is conjugated to the functional group at the distal end of the side chain from the α -carbon. The normal ability of the Lys, Arg, Orn or Cys side chain to participate in interactions mediated by that functional group (e.g. intra- and inter-molecular interactions) may therefore be reduced or completely eliminated by the presence of the substituent. Thus, the overall properties of the compound may be relatively insensitive to changes in the actual amino acid present as residue ψ . Consequently, it is believed that any of the residues Lys, Arg, Orn and Cys may be present at any position where ψ is permitted. However, in certain embodiments, it may be advantageous that the amino acid component of ψ is Lys.

[0106] Thus, ψ is a residue of Lys, Arg, Orn or Cys in which the side chain is conjugated to a substituent having the formula $-Z^1$ or $-Z^2-Z^1$.


[0107] $-Z^1$ is a fatty chain having at a terminus a connection $-X-$ to ψ or to Z^2 ;

[0108] wherein

[0109] $-X-$ is a bond, $-\text{CO}-$, $-\text{SO}-$, or $-\text{SO}_2-$;

[0110] and, optionally, Z^1 has a polar group at the end of the chain distal from connection $-X-$; said polar group comprising a carboxylic acid or a carboxylic acid bioisostere, a phosphonic acid, or a sulfonic acid group;

[0111] and wherein $-Z^2-$, if present, is a spacer of formula:



[0112] connecting Z^1 to ψ ;

[0113] wherein:

[0114] each Y is independently $-\text{NH}-$, $-\text{NR}-$, $-\text{S}-$ or $-\text{O}-$, where R is alkyl, a protecting group or forms a linkage to another part of the spacer Z^2 ;

[0115] each X is independently a bond, $\text{CO}-$, $\text{SO}-$, or SO_2- ;

[0116] with the proviso that when Y is $-\text{S}-$, the X to which it is bound is a bond;

[0117] each V is independently a bivalent organic moiety linking Y and X;

[0118] and n is 1-10.

[0119] The group Z^1

[0120] Z^1 is a fatty chain having a connection to ψ or to Z^2 , referred to herein as $-X-$. $-X-$ may be, for example, a bond, acyl ($-\text{CO}-$), sulfinyl ($-\text{SO}-$), or sulfonyl ($-\text{SO}_2-$). When Z^1 is bound directly to ψ , that is, when Z^2 is not present, preferably $-X-$ is acyl ($-\text{CO}-$), sulfinyl ($-\text{SO}-$), or sulfonyl ($-\text{SO}_2-$). Most preferably, $-X-$ is acyl ($-\text{CO}-$).


[0121] Z^1 may further have a polar group, said polar group being located at the end of the chain distal from the connection $-X-$. In other words, the connection is located

at the ω -position with respect to the polar group. The polar group may be bound directly to the terminus of the fatty chain, or may be bound via a linker.

[0122] Preferably, the polar group is an acidic or weakly acid group, for example a carboxylic acid or a carboxylic acid bioisostere, a phosphonate, or a sulfonate. The polar group may have a pK_a of between -2 and 12 in water, more preferably between 1 and 7 , more preferably between 3 and 6 . Certain preferred polar groups have a pK_a of between 4 and 5 .


[0123] For example, and not by way of limitation, the polar group may comprise a carboxylic acid ($-\text{COOH}$) or a carboxylic acid bioisostere, a phosphonic acid ($-\text{P}(\text{O})(\text{OH})_2$), or a sulfonic acid ($-\text{SO}_2\text{OH}$) group.

[0124] Preferably the polar group, if present, comprises a carboxylic acid or carboxylic acid bioisostere. Suitable carboxylic acid bioisosteres are known in the art. Preferably the bioisostere has a proton having a pK_a similar to the corresponding carboxylic acid. Examples of suitable bioisosteres may include, not by way of limitation, tetrazole, acylsulfonamides, acylhydroxylamine, and squaric acid derivatives, as shown below (--- indicates the point of attachment):



[0125] Fatty chain as used herein refers to a moiety comprising a chain of carbon atoms, the carbon atoms being predominantly substituted with hydrogen or hydrogen-like atoms, for example, a hydrocarbon chain. Such fatty chains are often referred to as lipophilic, although it will be appreciated that substitution may alter the lipophilic properties of the overall molecule.

[0126] The fatty chain may be aliphatic. It may be entirely saturated or may include one or more double or triple bonds. Each double bond, if present, may be in the E or Z configuration. The fatty chain may also have one or more cycloalkylene or heterocycloalkylene moieties in its length, and additionally or alternatively may have one or more arylene or heteroarylene moieties in its length. For example, the fatty chain may incorporate a phenylene or piperazinylene moiety in its length as, for example, shown below (wherein --- represents the points of attachment within the chain).



[0127] The fatty chain may be derived from a fatty acid, for example, it may be derived from a medium-chain fatty acid (MCFA) with an aliphatic tail of 6-12 carbon atoms, a long-chain fatty acid (LCFA) with an aliphatic tail of 13-21 carbon atoms, or a very long-chain fatty acid (VLCFA) with an aliphatic tail of 22 carbon atoms or more. Examples of linear saturated fatty acids from which suitable fatty chains may be derived include tridecyl (tridecanoic) acid, myristic (tetradecanoic) acid, pentadecyl (pentadecanoic) acid, palmitic (hexadecanoic) acid, and margaric (heptadecanoic) acid. Examples of linear unsaturated fatty acids from which suitable fatty chains may be derived include myristoleic acid, palmitoleic acid, sapienic acid and oleic acid.

[0128] The fatty chain may be connected to ψ or to Z^2 by an amide linkage, a sulfinamide linkage, a sulfonamide linkage, or by an ester linkage, or by an ether, thioether or amine linkage. Accordingly, the fatty chain may have, a bond to ψ or to Z^2 or an acyl ($-\text{CO}-$), sulfinyl ($-\text{SO}-$), or sulfonyl ($-\text{SO}_2-$) group. Preferably, the fatty chain has a terminus having an acyl ($-\text{CO}-$) group and is connected to ψ or Z^2 by an amide or ester linkage.

[0129] In some embodiments, Z^1 is a group of formula:



[0130] wherein

[0131] A is hydrogen or a carboxylic acid, a carboxylic acid bioisostere, a phosphonic acid, or a sulfonic acid group;

[0132] B is a bond or a linker;

[0133] X is a bond, acyl ($-\text{CO}-$), sulfinyl ($-\text{SO}-$), or sulfonyl ($-\text{SO}_2-$); and

[0134] Alk is a fatty chain that may be optionally substituted with one or more substituents. The fatty chain is preferably 6 to 28 carbon atoms in length (e.g. a C_{6-28} alkylene), more preferably, 12 to 26 carbons in length (e.g. a C_{12-26} alkylene), more preferably, 16 to 22 carbons in length (e.g. C_{16-22} alkylene), and may be saturated or unsaturated. Preferably, Alk is saturated, that is, preferably Alk is alkylene.


[0135] Optional substituents on the fatty chain may be independently selected from fluoro, C_{1-4} alkyl, preferably methyl; trifluoromethyl, hydroxymethyl, amino, hydroxyl, C_{1-4} alkoxy, preferably methoxy; oxo, and carboxyl, and may be independently located at any point along the chain. In some embodiments, each optional substituent is selected from fluoro, methyl, and hydroxyl. Where more than one substituent is present, substituents may be the same or different. Preferably, the number of substituents is 0 to 3; more preferably the fatty chain is unsubstituted.

[0136] B may be a bond or a linker. When B is a linker, it may be a cycloalkylene, heterocycloalkylene, C_6 arylene, or C_{5-6} heteroarylene, or C_6 arylene-O- or C_{5-6} heteroarylene-O-.

[0137] When B is phenylene it may, for example, be selected from 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, preferably 1,4-phenylene (so that A-B- is a 4-benzoic acid substituent or 4-benzoic acid bioisostere). When B is phenylene-O-, it may, for example, be selected from 1,2-phenylene-O-, 1,3-phenylene-O-, 1,4-phenylene-O-, preferably 1,4-phenylene-O-. Each phenylene of B may be optionally substituted with one or more substituents selected from fluoro, methyl, trifluoromethyl, amino, hydroxyl, and C_{1-4} alkoxy, preferably methoxy. It will be appreciated that substituent identity and position may be selected to subtly alter the pK_a of the polar group. Suitable inductively or

mesomerically electron-withdrawing or donating groups and their positional effects are known in the art. In some embodiments, B may be C_{5-6} heteroarylene, for example, pyridinylene or thiofuranylene, and may be optionally substituted as described.


[0138] For example, in some embodiments, A-B- may be selected from:




[0139] Preferably, is $\text{H}-$ or $\text{HOOC}-$ and B is a bond.

[0140] It will be understood that when A is hydrogen, B is a bond and Alk is unsubstituted alkylene, A-B-Alk- is an alkyl chain of formula $\text{H}_3\text{C}-(\text{CH}_2)_n-$.


[0141] In some embodiments, Z^1 is an acyl group of formula:



[0142] or a sulfonyl group of formula:



[0143] Preferably, Z^1 is an acyl group of formula:



[0144] where A and B are as defined above.

[0145] In some embodiments, A is $-\text{COOH}$ and B is a bond. Accordingly, certain preferred Z^1 are derived from long-chain saturated α,ω -dicarboxylic acids of formula $\text{HOOC}-(\text{CH}_2)_{12-22}-\text{COOH}$, preferably, long-chain saturated α,ω -dicarboxylic acids having an even number of carbon atoms in the aliphatic chain. In some other embodiments, A is H and B is a bond. Accordingly, certain preferred Z^1 are derived from long-chain saturated carboxylic acids of formula $\text{HOOC}-(\text{CH}_2)_{12-22}-\text{CH}_3$, preferably, long-chain saturated carboxylic acids having an even number of carbon atoms in the aliphatic chain.

[0146] For example, and not by way of limitation, Z^1 may be:

[0147] $\text{A-B-C}_{16-20}\text{alkylene}(\text{CO})-$ wherein A is H or $-\text{COOH}$ and B is a bond, for example:

[0148] 17-carboxy-heptadecanoyl $\text{HOOC}-(\text{CH}_2)_{16}-(\text{CO})-$;

[0149] 19-carboxy-nonadecanoyl $\text{HOOC}-(\text{CH}_2)_{18}-(\text{CO})-$;


[0150] Octadecanoyl $\text{H}_3\text{C}-(\text{CH}_2)_{16}-(\text{CO})-$;

[0151] Eicosanoyl $\text{H}_3\text{C}-(\text{CH}_2)_{18}-(\text{CO})-$;

[0152] The carboxylic acid group, if present, may be replaced by a bioisostere as detailed herein.

[0153] The Group Z^2

[0154] Z^2 is an optional spacer that connects Z^1 to the side chain of the amino acid component of ψ . At its most general, Z^2 , if present, is a spacer bound at one terminus by Y, which may be a nitrogen, oxygen or sulfur atom, and at the other terminus by X, which may be a bond or an acyl ($-\text{CO}-$), sulfinyl ($-\text{SO}-$), sulfonyl ($-\text{SO}_2-$) or absent. Accordingly, Z^2 may be a spacer of formula (--- indicate points of attachment):



[0155] wherein:

[0156] Y may be —NH— , —NR— , —S— or —O— , where R may be alkyl, a protecting group or may form a linkage to another part of the spacer, with the remaining valency forming a linkage to Z^1 ;

[0157] X may be a bond, CO— , SO— , or $\text{SO}_2\text{—}$, with the remaining valency forming a linkage to the side chain of the amino acid component of Y;

[0158] V is a bivalent organic moiety linking Y and X;

[0159] and n may be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. Where n is 2 or more, each Y, V, and X is independent of every other Y, V, and X.

[0160] Accordingly, Z^2 may be bound at each side by amide, sulfonamide, sulfonamide, or ester linkages or by amino, ether, or thioether linkages depending upon the nature of Y and X and the corresponding linking groups on Z^1 and the side chain. Where n is 2 or greater, each V may also be bound to each adjacent V by linkages as described. Preferably, linkages are amides, esters or sulfonamides, most preferably amides. Accordingly, in some embodiments, each Y is —NH— or —NR— and each X is CO— or $\text{SO}_2\text{—}$. Most preferably, —X— is acyl (—CO—).

[0161] In some embodiments, Z^2 is a spacer of formula $\text{—S}_A\text{—}$, $\text{—S}_B\text{—}$, $\text{—S}_A\text{—S}_B\text{—}$ or $\text{—S}_B\text{—S}_A\text{—}$, wherein S_A and S_B are as defined below.

[0162] In some embodiments, Z^2 is selected from $\text{—S}_A\text{—}$ or $\text{—S}_B\text{—S}_A\text{—}$, that is, [side chain]— Z^2 Z^1 is [side chain]— S_A — Z^1 or [side chain]— S_B — S_A — Z^1 .


[0163] The Group S_A

[0164] S_A may be a single amino acid residue or a residue of an amino acid derivative, especially an amino acid derivative residue having a sulfinyl or sulfonyl in place of the carboxy moiety at the C terminus. Additionally or alternatively, the single amino acid residue may have an oxygen or sulfur atom in place of the nitrogen atom at the N terminus. Preferably, S_A is a single amino acid residue.


[0165] In some embodiments, the amino acid may be selected from γ -Glu, α -Glu, α -Asp, β -Asp, Ala, β -Ala (3-aminopropanoic acid), Dapa (2,3-diaminopropanoic acid), Dab (2,4-diaminobutanoic acid), and Gaba (4-aminobutanoic acid). It will be understood that where more than one carboxylic acid or amino moiety is present, connection may be at any moiety as appropriate. Any carboxylic acid or amino residues not bound within the residue may be free, that is, present as a free carboxylic acid or primary amine, or may be derivatised. Suitable derivatisation is known in the art. For example, carboxylic acid moieties may be present in S_A amino acid residues as esters, for example, as methyl esters. Amino moieties may be present as alkylated amines, for example, methylated, or may be protected as amide or carbamate moieties. Other suitable amino acids include β -Ala (3-aminopropanoic acid) and Gaba (4-aminobutanoic acid) and similar w amino acids.

[0166] It will be understood that amino acids may be D or L, or a racemic or enantioenriched mixture. In some embodiments, the amino acid is an L-amino acid. In some embodiments, the amino acid is a D-amino acid.

[0167] In some preferred embodiments, S_A has a carboxylic acid substituent, with γ -Glu, α -Glu, α -Asp, and β -Asp, and sulfinyl and sulfonyl derivatives thereof, being preferred. Accordingly, in some embodiments, the amino acid residue is:



[0168] where —X— is —CO— , —SO— , $\text{—SO}_2\text{—}$, preferably —CO— , and a is 1 or 2, preferably 2. In some embodiments, the carboxylic acid is an ester, and the amino acid residue is:



[0169] where —X— is —CO— , —SO— , $\text{—SO}_2\text{—}$, preferably —CO— , and a is 1 or 2, preferably 2, and R is C_{1-4} alkyl or C_6 aryl. Preferably R is C_{1-4} alkyl, preferably methyl or ethyl, more preferably ethyl.

[0170] A preferred S_A group bearing a carboxylic acid is γ -Glu.

[0171] Preferably, S_A is selected from Dapa or γ -Glu. Most preferably, S_A is γ -Glu.


[0172] The Group S_B

[0173] S_B may be a linker of general formula:



[0174] wherein P_U is a polymeric unit and n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. One terminus of the linker S_B is an —NH— , —NR— , —S— or —O— , wherein R may be alkyl, a protecting group or may form a linkage to another part of the polymeric unit; while the other is a bond or CO— , SO— or $\text{SO}_2\text{—}$. Accordingly, each polymeric unit P_U may be bound at each side by amide, sulfonamide, sulfonamide, or ester linkages or by amino, ether, or thioether linkages depending upon the nature of Y and X and the corresponding linking groups on Z^1 , S_A , and Lys.

[0175] In some embodiments, each P_U may be independently a unit of formula:



[0176] wherein:

[0177] Y may be —NH— , —NR— , —S— or —O— , wherein R may be alkyl, a protecting group or may form a linkage to another part of the spacer, with the remaining valency forming a linkage to Z^1 ;

[0178] X may be a bond, CO— , SO— , or $\text{SO}_2\text{—}$, with the remaining valency forming a linkage to the ψ side chain;

[0179] and V is a bivalent organic moiety linking Y and X.

[0180] In some embodiments, V is the α -carbon of a natural or unnatural amino acid, that is V is $\text{—CHR}^{AA}\text{—}$, wherein R^{AA} is an amino acid side chain; or V is an

optionally substituted C_{1-6} alkylene, or V is a chain comprising one or more units of ethylene glycol in series, also known as PEG chain, for example, $-\text{CH}_2\text{CH}_2-(\text{OCH}_2\text{CH}_2)_m-\text{O}-(\text{CH}_2)_p-$, where m is 0, 1, 2, 3, 4, or 5, and p is 1, 2, 3, 4, or 5; when X is $\text{CO}-$, p is preferably 1, 3, 4, or 5. Optional alkylene substituents include fluoro, methyl, hydroxy, hydroxymethyl, and amino.

[0181] Preferred P_U units include:

[0182] (i). Single amino acid residues: P_U^i ;

[0183] (ii). Dipeptide residues: P_U^{ii} ; and

[0184] (iii). Amino-(PEG) $_m$ -carboxylic acid residues: P_U^{iii} .

[0185] and may be present in any combination or order. For example, S_B may comprise one or more of each of P_U^i , P_U^{ii} , and P_U^{iii} in any order, or may comprise one or more units of P_U^i , P_U^{ii} , and P_U^{iii} only, or one of more units selected from P_U^i and P_U^{ii} , P_U^i and P_U^{iii} , or P_U^{ii} and P_U^{iii} .

[0186] (1). P_U^i single amino acid residues

[0187] Each P_U^i may be independently selected from any natural or unnatural amino acid residue and, for example, may be selected from Gly, Pro, Ala, Val, Leu, Ile, Met, Cys, Phe, Tyr, Trp, His, Lys, Arg, Gln, Asn, α -Glu, γ -Glu, Asp, Ser, Thr, Dapa, Gaba, Aib, β -Ala, 5-aminopentanoyl, 6-aminohexanoyl, 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl, and 10-aminodecanoyl. Preferably, P_U^i amino acid residues are selected from Gly, Ser, Ala, Thr, and Cys, more preferably from Gly and Ser.

[0188] In some embodiments, S_B is $-(P_U^i)_n-$, wherein n is 1 to 8, more preferably 5 to 7, most preferably 6. In some preferred embodiments, S_B is $-(P_U^i)_n-$, n is 6 and each P_U^i is independently selected from Gly or Ser, with a preferred sequence being -Gly-Ser-Gly-Ser-Gly-Gly- (SEQ ID NO: 114).

[0189] (ii). P_U^{ii} dipeptide residues Each P_U^{ii} may be independently selected from any dipeptide residue comprising two natural or unnatural amino acid residues bound by an amide linkage. Preferred P_U^{ii} dipeptide residues include Gly-Gly, Gly-Ser, Ser-Gly, Gly-Ala, Ala-Gly, and Ala-Ala, more preferably Gly-Ser and Gly-Gly.

[0190] In some embodiments, S_B is $-(P_U^{ii})_n-$, wherein n is 2 to 4, more preferably 3, and each P_U^{ii} is independently selected from Gly-Ser and Gly-Gly. In some preferred


embodiments S_B is $-(P_U^{ii})_n-$, n is 3 and each P_U^{ii} is independently selected from Gly-Ser and Gly-Gly, with a preferred sequence being -(Gly-Ser)-(Gly-Ser)-(Gly-Gly) (SEQ ID NO: 114).

[0191] Amino acids having stereogenic centres within P_U^i and P_U^{ii} may be racemic, enantioenriched, or enantiopure. In some embodiments, the or each amino acid is independently an L-amino acid.

[0192] In some embodiments, the or each amino acid is independently a D-amino acid.

[0193] (iii). P_U^{iii} amino-(PEG) $_m$ -carboxylic acid residues

[0194] Each P_U^{iii} may be independently a residue of general formula:



[0195] wherein m is 0, 1, 2, 3, 4, or 5, preferably 1 or 2, and p is 1, 3, 4, or 5, preferably 1.

[0196] In some embodiments, m is 1 and p is 1, that is, P_U^{iii} is a residue of 8-amino-3,6-dioxaoctanoic acid (also known as {2-[2-aminoethoxy]ethoxy}acetic acid and $\text{H}_2\text{N}-\text{PEG}_3-\text{COOH}$). This residue is referred to herein as -PEG $_3$ -.

[0197] Other, longer, PEG chains are also known in the art. For example, 11-amino-3,6,9-trioxaundecanoic acid (also known as $\text{H}_2\text{N}-\text{PEG}_4-\text{COOH}$ or -PEG $_4$ -).


[0198] In some embodiments, S_B is $-(P_U^{iii})_n-$, wherein n is 1 to 3, more preferably 2.

[0199] Most preferably, S_B is -PEG $_3$ -PEG $_3$ -.

[0200] Preferred Combinations

[0201] It will be understood that the above preferences may be independently combined to give preferred $-Z^1$ and $-Z^2-Z^1$ moieties.


[0202] Some preferred $-Z^1$ and $-Z^2-Z^1$ moieties are shown below (in each case, -- indicates the point of attachment to the side chain of the amino acid component of ψ):



[17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3


(i)

-continued




(ii)

[17-carboxy-heptadecanoyl]-isoGlu



(iii)


Octadecanoyl-isoGlu-Peg3-Peg3



(iv)


Eicosanoyl-isoGlu-Peg3-Peg3

-continued




[19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3

(v)



Octadecanoyl-Dapa-Peg3-Peg3

(vi)



Hexadecanoyl-isoGlu

(vii)

[0203] The skilled person will be well aware of suitable techniques for preparing the compounds employed in the context of the invention. For examples of suitable chemistry, see, e.g., WO98/08871, WO00/55184, WO00/55119, Madsen et al. (*J. Med. Chem.* 2007, 50, 6126-32), and Knudsen et al. 2000 (*J. Med. Chem.* 43, 1664-1669).

[0204] Clinical Utility

[0205] The compounds of the invention may provide an attractive treatment option for metabolic diseases including obesity and diabetes mellitus (diabetes). Diabetes comprises a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Acute signs of diabetes include excessive urine production, resulting compensatory thirst and increased fluid intake, blurred vision, unexplained weight loss, lethargy, and changes in energy metabolism. However, symptoms are often not severe or may be absent. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs,

notably the eyes, kidneys, nerves, heart and blood vessels. Diabetes is classified into type 1 diabetes, type 2 diabetes and gestational diabetes on the basis on pathogenetic characteristics. Type 1 diabetes accounts for 5-10% of all diabetes cases and is caused by auto-immune destruction of insulin-secreting pancreatic β -cells.

[0206] Type 2 diabetes accounts for 90-95% of diabetes cases and is a result of a complex set of metabolic disorders. However, symptoms are often not severe or may be absent. Type 2 diabetes is the consequence of endogenous insulin production becoming insufficient to maintain plasma glucose levels below diagnostic thresholds.

[0207] Gestational diabetes refers to any degree of glucose intolerance identified during pregnancy.

[0208] Pre-diabetes includes impaired fasting glucose and impaired glucose tolerance and refers to those states that occur when blood glucose levels are elevated but below the levels that are established for the clinical diagnosis for diabetes.

[0209] A large proportion of people with type 2 diabetes and pre-diabetes are at increased risk of morbidity and mortality due to the high prevalence of additional metabolic risk factors, including abdominal obesity (excessive fat tissue around the abdominal internal organs), atherogenic dyslipidemia (blood fat disorders including high triglycerides, low HDL cholesterol and/or high LDL cholesterol, which foster plaque buildup in artery walls), elevated blood pressure (hypertension) a prothrombotic state (e.g. high fibrinogen or plasminogen activator inhibitor-1 in the blood), and/or a proinflammatory state (e.g., elevated C-reactive protein in the blood).

[0210] Conversely, obesity confers an increased risk of developing pre-diabetes, type 2 diabetes as well as, e.g., certain types of cancer, obstructive sleep apnea and gallbladder disease.

[0211] Dyslipidemia is associated with increased risk of cardiovascular disease. High Density Lipoprotein (HDL) is of clinical importance since an inverse correlation exists between plasma HDL concentrations and risk of atherosclerotic disease. The majority of cholesterol stored in atherosclerotic plaques originates from LDL and hence an elevated concentration of Low Density Lipoproteins (LDL) is closely associated with atherosclerosis. The HDL/LDL ratio is a clinical risk indicator for atherosclerosis and coronary atherosclerosis in particular.

[0212] Compounds employed in the context of the invention act as glucagon-GIP-GLP1 triple agonists. The triple agonist may combine the effect of glucagon, e.g., on fat metabolism with the effect of GIP on improved glycemic control and the effect of GLP-1 e.g., on blood glucose levels and food intake. They may therefore act to accelerate elimination of excessive adipose tissue, induce sustainable weight loss, and improve glycemic control. Triple glucagon-GIP-GLP1 agonists may also act to reduce cardiovascular risk factors such as high cholesterol and such as high LDL-cholesterol.

[0213] The triple agonist compounds of the present invention may therefore be used (alone or in combination) as pharmaceutical agents for preventing weight gain, promoting weight loss, reducing excess body weight or treating obesity (e.g., by control of appetite, feeding, food intake, calorie intake, and/or energy expenditure and lipolysis), including morbid obesity, as well as associated diseases and health conditions including but not limited to obesity linked inflammation, obesity linked gallbladder disease and obesity induced sleep apnea. The compounds may also be used for treatment of insulin resistance, glucose intolerance, pre-diabetes, increased fasting glucose, type 2 diabetes, hypertension, dyslipidemia (or a combination of these metabolic risk factors), atherosclerosis, arteriosclerosis, coronary heart disease, peripheral artery disease and stroke. These are all conditions which may be associated with obesity. However, the effects of the compounds employed in the context of the invention on these conditions may be mediated in whole or in part via an effect on body weight, or may be independent thereof.

[0214] The triple agonist compounds may thus be used (alone or in combination) for the treatment and/or prevention of any of the diseases, disorders, or conditions described herein, including insulin resistance, glucose intolerance, increased fasting glucose, pre-diabetes, type 1 diabetes, type 2 diabetes, gestational diabetes hypertension, dyslipidemia, or a combination thereof. In certain embodiments, the dia-

betes related disorder is selected from atherosclerosis, arteriosclerosis, coronary heart disease, peripheral artery disease and stroke; or associated with a condition selected from atherogenic dyslipidemia, blood fat disorders, elevated blood pressure, hypertension, a prothrombotic state, and proinflammatory state, or a combination thereof. In certain embodiments, the blood fat disorder is selected from high triglycerides, low HDL cholesterol, high LDL cholesterol, plaque buildup in artery walls, or a combination thereof. In certain embodiments, the prothrombotic state is selected from high fibrinogen levels in the blood and high plasminogen activator inhibitor-1 levels in the blood. In certain embodiments, the proinflammatory state is an elevated C-reactive protein level in the blood. In certain embodiments, the obesity related disorder is selected from obesity linked inflammation, obesity linked gallbladder disease and obesity induced sleep apnea.

[0215] The triple agonist compounds may also be used for the treatment and/or prevention of any of the diseases, disorders, or conditions associated with diabetes related osteoporosis including increased risk of bone fractures. The observed increase in fracture risk is likely to be related to impaired bone quality rather than to bone mineral density. The related mechanisms, due at least in part to hyperglycemia, neuropathy, and higher incidence of hypovitaminosis D, are not yet fully understood.

[0216] The invention provides the use of a triple agonist compound as described, in the manufacture of a medicament for any of the clinical applications described in this specification. Reference to a compound for use in any such method should be construed accordingly.

[0217] In some embodiments, the invention also provides a therapeutic kit comprising a triple agonist of the invention, optionally in combination with a pharmaceutically acceptable carrier. In some embodiments, the invention provides a device comprising a triple agonist of the invention for delivery of the triple agonist to a subject.

[0218] Pharmaceutical Compositions

[0219] The triple agonist compounds of the present invention, or salts or solvates thereof, may be formulated as pharmaceutical compositions prepared for storage or administration, which typically comprise a therapeutically effective amount of a compound employed in the context of the invention, or a salt or solvate thereof, in a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is formulated as a liquid suitable for administration by injection or infusion, or which is formulated to cause slow release of the triple agonist compound

[0220] The therapeutically effective amount of a compound of the present invention will depend, e.g., on the route of administration, the type of mammal being treated, and the physical characteristics of the specific mammal under consideration. These factors and their relationship to determining this amount are well known to skilled practitioners in the medical arts. This amount and the method of administration can be tailored to achieve optimal efficacy, and may depend on such factors as weight, diet, concurrent medication and other factors, well known to those skilled in the medical arts. The dosage sizes and dosing regimen most appropriate for human use may be guided by the results obtained by the present invention, and may be confirmed in properly designed clinical trials.

[0221] An effective dosage and treatment protocol may be determined by conventional means, starting with a low dose

in laboratory animals and then increasing the dosage while monitoring the effects, and systematically varying the dosage regimen as well. Numerous factors may be taken into consideration by a clinician when determining an optimal dosage for a given subject. Such considerations are known to the skilled person. The term “pharmaceutically acceptable carrier” includes any of the standard pharmaceutical carriers. Pharmaceutically acceptable carriers for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington’s Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). For example, sterile saline and phosphate-buffered saline at slightly acidic or physiological pH may be used. Suitable pH buffering agents may be, e.g., phosphate, citrate, acetate, lactate, maleate, tris(hydroxymethyl)aminomethane (TRIS), N-Tris(hydroxymethyl)methyl-3-aminopropanesulphonic acid (TAPS), ammonium bicarbonate, diethanolamine, histidine, which in certain embodiments is a preferred buffer, arginine, lysine, or acetate or mixtures thereof. The term further encompasses any agents listed in the US Pharmacopeia for use in animals, including humans.

[0222] The term “pharmaceutically acceptable salt” refers to a salt of the compound. Salts include pharmaceutically acceptable salts, such as, e.g., acid addition salts and basic salts. Examples of acid addition salts include hydrochloride salts, citrate salts and acetate salts. Examples of basic salts include salts where the cation is selected from alkali metals, such as sodium and potassium, alkaline earth metals such as calcium, and ammonium ions $N(R^3)_3(R^4)$, where R^3 and R^4 independently designate optionally substituted C_{1-6} -alkyl, optionally substituted C_{2-6} -alkenyl, optionally substituted aryl, or optionally substituted heteroaryl. Other examples of pharmaceutically acceptable salts are described in “Remington’s Pharmaceutical Sciences”, 17th edition. Ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and more recent editions, and in the Encyclopaedia of Pharmaceutical Technology.

[0223] “Treatment” is an approach for obtaining beneficial or desired clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” may also mean prolonging survival as compared to expected survival if not receiving treatment. “Treatment” is an intervention performed with the intention of preventing the development or altering the pathology of a disorder. Accordingly, “treatment” refers to both therapeutic treatment and prophylactic or preventative measures in certain embodiments. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented. By treatment is meant inhibiting or reducing an increase in pathology or symptoms (e.g. weight gain, hyperglycemia) when compared to the absence of treatment, and is not necessarily meant to imply complete cessation of the relevant condition.

[0224] The pharmaceutical compositions of the invention may be in unit dosage form. In such form, the composition is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets,

capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms. It may be provided in single dose injectable form, for example in the form of an injection pen. Compositions may be formulated for any suitable route and means of administration. Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, rectal, nasal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, and transdermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Subcutaneous or transdermal modes of administration may be particularly suitable for certain of the compounds described herein.

[0225] Combination Therapy

[0226] In certain embodiments, a compound of the invention may be administered as part of a combination therapy with at least one other agent for treatment of diabetes, obesity, dyslipidemia, or hypertension.

[0227] In such cases, the at least two active agents may be given together or separately, and as part of the same pharmaceutical formulation or as separate formulations. Thus, the triple agonist compound (or the salt or solvate thereof) may be used in combination with an antidiabetic agent including but not limited to metformin, a sulfonylurea, a glinide, a DPP-IV inhibitor, a glitazone, or insulin. In certain embodiments, the compound or salt or solvate thereof is used in combination with insulin, DPP-IV inhibitor, sulfonylurea or metformin, particularly sulfonylurea or metformin, for achieving adequate glycemic control. In certain preferred embodiments, the compound or salt or solvate thereof is used in combination with insulin or an insulin analogue for achieving adequate glycemic control. Examples of insulin analogues include but are not limited to LANTUS®, NOVORAPID®, HUMALOG®, NOVOMIX®, ACTRAPHANE HM®, LEVEMIR® and APIDRA®.

[0228] In certain embodiments, the triple agonist compound or salt or solvate thereof may further be used in combination with one or more of an anti-obesity agent, including but not limited to a glucagon-like peptide receptor 1 agonist, peptide YY or analogue thereof, cannabinoid receptor 1 antagonist, lipase inhibitor, melanocortin receptor 4 agonist, or melanin concentrating hormone receptor 1 antagonist.

[0229] In certain embodiments, the triple agonist compound or salt or solvate thereof may be used in combination with an anti-hypertension agent, including but not limited to an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, diuretics, beta-blocker, or calcium channel blocker.

[0230] In certain embodiments, the triple agonist compound or salt thereof may be used in combination with an anti-dyslipidemia agent, including but not limited to a statin, a fibrate, a niacin and/or a cholesterol absorption inhibitor.

[0231] Nucleic Acids, Vectors, and Host Cells

[0232] The invention provides a nucleic acid encoding a peptide having the sequence X1-X30 of Formula I. Also provided is an expression construct (also known as an expression vector) comprising a nucleic acid of the invention in operable linkage with suitable regulatory elements to direct expression of the peptide, e.g. transcription and translation. The invention also provides a host cell comprising a

nucleic acid or expression construct and capable of expressing, and optionally secreting, the peptide.

[0233] In some embodiments, the invention provides a method of producing a compound of the invention, the method comprising culturing the host cells described above under conditions suitable for expressing the compound and purifying the compound thus produced.

[0234] The invention also provides a nucleic acid molecule, an expression vector, or a host cell, as described above, for use in a method of medical treatment, and in particular for treatment of the metabolic disorders discussed elsewhere in this specification.

[0235] Synthesis of Compounds of the Invention

[0236] A nucleic acid molecule may encode a compound of the invention, a peptide having the amino acid sequence X1-X30 of Formula I, or a peptide which is a precursor of a compound of the invention.

[0237] Typically, such nucleic acid sequences will be provided as expression constructs wherein the encoding nucleic acid is in functional linkage with appropriate control sequences to direct its expression. The expression construct may be provided in the context of a host cell capable of expressing (and optionally also secreting) the precursor, or in a cell-free expression system.

[0238] The invention provides a method of producing a triple agonist of the invention, the method comprising expressing an amino acid precursor of the triple agonist and modifying the precursor to provide the triple agonist. The modification may comprise chemical modification of a Lys, Arg or Cys residue present at a position ψ to introduce the lipophilic moiety, modification of the N- or C-terminus, and/or modification of any other amino acid side chains in the molecule (e.g. to introduce a non-naturally occurring amino acid residue).

[0239] The compounds of the invention may also be manufactured by standard peptide synthetic methods, e.g. by standard solid-phase or liquid-phase methodology, either stepwise or by fragment assembly, and isolating and purifying the final peptide compound product, or by any combinations of recombinant and synthetic methods.

[0240] It may be preferable to synthesize the peptide compounds of the invention by means of solid-phase or liquid-phase peptide synthesis. In this context, reference may be made to WO 98/11125 or, inter alia, Fields, G. B. et al., "Principles and Practice of Solid-Phase Peptide Synthesis"; in: Synthetic Peptides, Gregory A. Grant (ed.), Oxford University Press (2nd edition, 2002) and the synthesis examples herein.

EXAMPLES

[0241] The following examples demonstrate certain embodiments of the present invention. However, it is to be understood that these examples neither purport nor are they intended to be wholly definitive as to conditions and scope of this invention. The examples were carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The following examples are presented for illustrative purposes only, and should not be construed in any way as limiting the scope of this invention.

[0242] All publications, patents, and patent applications referred to herein are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

Example 1

[0243] The methods used in the instant invention are described below, except where expressly indicated otherwise.

[0244] General Synthesis of Acylated Triple Agonists
Solid phase peptide synthesis was performed on a CEM Liberty Peptide Synthesizer using standard Fmoc chemistry. TentaGel S Ram resin (1 g; 0.25 mmol/g) was swelled in NMP (10 ml) prior to use and transferred between tube and reaction vessel using DCM and NMP.

[0245] Coupling

[0246] An Fmoc-amino acid in NMP/DMF/DCM (1:1:1; 0.2 M; 5 ml) was added to the resin in a CEM Discover microwave unit together with COMU/NMP (0.5 M; 2 ml) and DIPEA/DMF (2.0 M; 1 ml). The coupling mixture was heated to 75° C. for 5 min while nitrogen was bubbled through the mixture. The resin was then washed with DMF (4×10 ml).

[0247] Deprotection

[0248] Piperidine/NMP (20%; 10 ml) was added to the resin for initial deprotection and the mixture was heated by microwaves (30 sec; 40° C.). The reaction vessel was drained and a second portion of piperidine/DMF (20%; 10 ml) was added and heated (75° C.; 3 min.) again. The resin was then washed with NMP (6×10 ml).

[0249] Side Chain Acylation

[0250] Fmoc-Lys(ivDde)-OH or alternatively another amino acid with an orthogonal side chain protective group was introduced at the position of the acylation. The N-terminal of the peptide backbone was then Boc-protected using Boc2O or alternatively by using a Boc-protected amino acid in the last coupling. While the peptide was still attached to the resin, the orthogonal side chain protective group was selectively cleaved using freshly prepared hydrazine hydrate (2-4%) in NMP for 2×15 min. The unprotected lysine side chain was first coupled with Fmoc-Glu-OtBu or another spacer amino acid, which was deprotected with piperidine and acylated with a lipophilic moiety using the peptide coupling methodology as described above. Abbreviations employed are as follows:

[0251] COMU: 1-[(1-(cyano-2-ethoxy-2-oxoethylideneaminoxy)-dimethylamino-morpholinomethylene)]methanaminium hexafluorophosphate

[0252] ivDde: 1-(4,4-dimethyl-2,6-dioxocyclohexylidene) 3-methyl-butyl

[0253] Dde: 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-ethyl

[0254] DCM: dichloromethane

[0255] DMF: N,N-dimethylformamide

[0256] DIPEA: diisopropylethylamine

[0257] EtOH: ethanol

[0258] Et₂O: diethyl ether

[0259] HATU: N-[(dimethylamino)-1H-1,2,3-triazol[4,5-b]pyridine-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide

[0260] MeCN: acetonitrile

[0261] NMP: N-methylpyrrolidone

[0262] TFA: trifluoroacetic acid

[0263] TIS: triisopropylsilane

[0264] Cleavage

[0265] The resin was washed with EtOH (3×10 ml) and Et₂O (3×10 ml) and dried to constant weight at room temperature (r.t.). The crude peptide was cleaved from the resin by treatment with TFA/TIS/water (95/2.5/2.5; 40 ml, 2 h; r.t.). Most of the TFA was removed at reduced pressure

and the crude peptide was precipitated and washed three times with diethylether and dried to constant weight at room temperature.

[0266] HPLC Purification of the Crude Peptide

[0267] The crude peptide was purified to greater than 90% by preparative reverse phase HPLC using a PerSeptive Biosystems VISION Workstation equipped with a C-18

column (5 cm; 10 μ m) and a fraction collector and run at 35 ml/min with a gradient of buffer A (0.1% TFA, aq.) and buffer B (0.1% TFA, 90% MeCN, aq.). Fractions were analyzed by analytical HPLC and MS and relevant fractions were pooled and lyophilized. The final product was characterized by HPLC and MS. The synthesized compounds are shown in Table 1:

TABLE 1

Compound No	Sequence
1	H-YSQGTFTSDYSKYLDSKAAHDFVEWLLRA-NH ₂ (SEQ ID NO: 1)
2	H-Y-Aib-QGTFTSDYSKYLDS-K(Hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH ₂ (SEQ ID NO: 2)
3	H-Y-Aib-QGTFTSDYSKYLDSKAAHDFVEWLLRA-NH ₂ (SEQ ID NO: 3)
4	H-YSQGTFTSDYSKYLD-K(Hexadecanoyl-isoGlu)-KAAHDFVEWLLRA-NH ₂ (SEQ ID NO: 4)
5	H-Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA-NH ₂ (SEQ ID NO: 5)
6	H-Y-Aib-QGTFTSDYSKYLDKAAHDFVEWLLSA-NH ₂ (SEQ ID NO: 6)
7	H-Y-Aib-QGTFTSDYSKALDSKAAHDFVEWLLSA-NH ₂ (SEQ ID NO: 7)
8	H-Y-Aib-QGTFTSDYSKYLESKAAHDFVEWLLSA-NH ₂ (SEQ ID NO: 8)
9	H-Y-Aib-QGTFTSDYSIYLDEKAAHDFVEWLLSA-NH ₂ (SEQ ID NO: 9)
10	H-Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA-NH ₂ (SEQ ID NO: 10)
11	H-Y-Aib-QGTFTSDYSIYLDKAAHDFVNWLLSA-NH ₂ (SEQ ID NO: 11)
12	H-Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLRA-NH ₂ (SEQ ID NO: 12)
13	H-Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSAGPSSGAPPPS-NH ₂ (SEQ ID NO: 13)
14	H-Y-Aib-QGTFTSDYSIYLE-KKAAHDFVEWLLSA-NH ₂ (SEQ ID NO: 14)
15	H-Y-Aib-QGTFTSDYSIYLE-KKAAHDFVEWLLSA-NH ₂ (SEQ ID NO: 14)
16	H-Y-Aib-QGTFTSDYSIYLEKKAQKEFVEWLLSA-NH ₂ (SEQ ID NO: 15)
17	H-Y-Aib-QGTFTSDYSIYLDEKAAHDFVEWLLSA-NH ₂ (SEQ ID NO: 16)
18	H-Y-Aib-QGTFTSDYSIYLESKAAHDFVEWLLSA-NH ₂ (SEQ ID NO: 17)
19	H-Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA-NH ₂ (SEQ ID NO: 18)
20	H-Y-Aib-QGTFTSDYSIYLEKKAQKEFVEWLLSA-NH ₂ (SEQ ID NO: 19)
21	H-Y-Aib-QGTFTSDYSKALDEKAAKEFVEWLLSA-NH ₂ (SEQ ID NO: 20)
22	H-Y-Aib-QGTFTSDYSKYLEKKAQKEFVEWLLSA-NH ₂ (SEQ ID NO: 21)
23	H-Y-Aib-QGTFTSDYSIYLEK-K(Hexadecanoyl-isoGlu)-AAKEFVEWLLSA-NH ₂ (SEQ ID NO: 22)
24	H-Y-Aib-QGTFTSDYSIYLE-K(Hexadecanoyl-isoGlu)-KAAKEFVEWLLSA-NH ₂ (SEQ ID NO: 23)
25	H-Y-Aib-QGTFTSDYS-K(Hexadecanoyl-isoGlu)-YLEKKAKEFVEWLLSA-NH ₂ (SEQ ID NO: 24)
26	H-Y-Aib-QGTFTSDYSKYLDE-K(Hexadecanoyl-isoGlu)-AAKDFIEWLESA-NH ₂ (SEQ ID NO: 25)
27	H-Y-Aib-QGTFTSDYSIYLDK-K(Hexadecanoyl-isoGlu)-AAHDFVEWLLRA-NH ₂ (SEQ ID NO: 26)
28	H-Y-Aib-QGTFTSDYSIYLDE-K(Hexadecanoyl-isoGlu)-AAHDFVEWLLSA-NH ₂ (SEQ ID NO: 27)

TABLE 1-continued

Compound No	Sequence
29	H-Y-Aib-QGTFTSDYSIYLDK-K(Hexadecanoyl-isoGlu)-AAHDFVEWLLSAGPSSGAPPPS-NH ₂ (SEQ ID NO: 28)
30	H-Y-Aib-QGTFTSDYSIYLDE-K(Hexadecanoyl-isoGlu)-AAKDFVEWLESA-NH ₂ (SEQ ID NO: 29)
31	H-Y-Aib-QGTFTSDYSIYLDE-K(Hexadecanoyl-isoGlu)-AAKDFIEWLESA-NH ₂ (SEQ ID NO: 30)
32	H-Y-Aib-QGTFTSDYSIYLEK-K(isoGlu-Hexadecanoyl)-AAKEFVEWLLSAGPSSGAPPPS-NH ₂ (SEQ ID NO: 31)
33	H-Y-Aib-QGTFTSDYSIYLDK-K([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQGPSSGAPPPS-NH ₂ (SEQ ID NO: 32)
34	H-Y-Aib-QGTFTSDYSIYLDK-K([17-carboxy-heptadecanoyl]-isoGlu)-AQRAFVEWLLAQGPSSGAPPPS-NH ₂ (SEQ ID NO: 33)
35	H-Y-Aib-QGTFTSDYSIYLDK-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQGPSSGAPPPS-NH ₂ (SEQ ID NO: 34)
36	H-Y-Aib-QGTFTSDYSIYLDK-K(eicosanoyl-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQGPSSGAPPPS-NH ₂ (SEQ ID NO: 35)
37	H-Y-Aib-QGTFTSDYSIYLEK-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AAKEFVEWLLSAGPSSGAPPPS-NH ₂ (SEQ ID NO: 36)
38	H-Y-Aib-QGTFTSDYSIYLEK-K([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)-AAKEFVEWLLSAGPSSGAPPPS-NH ₂ (SEQ ID NO: 37)
39	H-Y-Aib-QGTFTSDYSIYLDE-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AAKEFIEWLESA-NH ₂ (SEQ ID NO: 38)
40	H-Y-Aib-QGTFTSDYSIYLDE-K([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)-AAKEFIEWLESA-NH ₂ (SEQ ID NO: 39)
41	H-Y-Ac4c-QGTFTSDYSIYLDE-K([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)-AAKEFIEWLESA-NH ₂ (SEQ ID NO: 40)
42	H-Y-Aib-QGTFTSDYSIALDK-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AQRAFVNWLV-Aib-KPSSGAPPPS-NH ₂ (SEQ ID NO: 41)
43	H-Y-Aib-QGTFTSDYSIALDK-K(Octadecanoyl-Dapa-Peg3-Peg3)-AQRAFVNWLV-Aib-KPSSGAPPPS-NH ₂ (SEQ ID NO: 42)
44	H-Y-Aib-QGTFTSDYSIALDK-K([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)-AQRAFVNWLV-Aib-KPSSGAPPPS-NH ₂ (SEQ ID NO: 43)
45	H-Y-Aib-QGTFTSDYSIALEK-K([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQK-NH ₂ (SEQ ID NO: 44)
46	H-Y-Aib-QGTFTSDYSIALEK-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQK-NH ₂ (SEQ ID NO: 45)
47	H-Y-Aib-QGTFTSDYSIALEK-K([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQK-NH ₂ (SEQ ID NO: 46)
48	H-Y-Aib-QGTFTSDLSIALEK-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQK-NH ₂ (SEQ ID NO: 47)
49	H-Y-Ac4c-QGTFTSDYSIALEK-K([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQK-NH ₂ (SEQ ID NO: 48)
50	H-Y-Aib-QGTFTSDYSIYLEK-K(Octadecanoyl-isoGlu-Peg3-Peg3)-AQRAFVEWLLRA-NH ₂ (SEQ ID NO: 49)
51	H-Y-Aib-QGTFTSDYSIYLEK-K([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)-AQRAFVEWLLRA-NH ₂ (SEQ ID NO: 50)
52	H-Y-Ac4c-QGTFTSDYSIYLDK-K([19-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)-AQRAFVEWLLAQGPSSGAPPPS-NH ₂ (SEQ ID NO: 51)

Example 2

[0268] Human GIP Receptor (GIP-R), GLP-1 Receptor (GLP-1-R) and Glucagon Receptor (GCG-R) Activity Assay

[0269] In vitro effects of peptide conjugates of the invention were assessed by measuring the induction of cAMP following stimulation of the respective receptor by glucagon, GIP, GLP1 or analogues of these as outlined in the invention, using the AlphaScreen® cAMP kit from Perkin-Elmer according to instructions. Briefly, HEK293 cells expressing the human GIP R, GLP-1 R or GCG R (stable cell lines generated through transfection of the cDNA for human GIP R, GLP-1 R or GCG R and selection of stable clones) were seeded at 30,000 cells/well in 96-well microtiter plates coated with 0.01% poly-L-lysine, and grown for 1 day in culture in 200 µl growth medium (DMEM, 10% FCS, Penicillin (100 IU/ml), Streptomycin (100 µg/ml)). On the day of analysis, growth medium was removed and the cells were washed once with 150 µl Tyrode's buffer (Tyrode's Salts (9.6 g/l), 10 mM HEPES, pH 7.4). Cells were then incubated in 100 µl Assay buffer (0.1% W/V Alkali-treated Casein and 100 µM IBMX in Tyrode's Buffer) containing increasing concentrations of control and test compounds for 15 min at 37° C. The Assay buffer was removed and cells are lysed in 80 µl Lysis buffer (0.1% w/v BSA, 5 mM HEPES, 0.3% v/v Tween-20) per well. From each well 10 µl of lysed cells were transferred to a 384-well plate and mixed with 15 µl bead-mix (1 Unit/15 µl anti-cAMP Acceptor Beads, 1 Unit/15 µl Donor Beads, and 1 Unit/15 µl Biotinylated cAMP in Assay Buffer). The plates were mixed and incubated in the dark for an hour at room temperature before measuring using an Envision™ plate reader (Perkin-Elmer).

[0270] Results were converted into cAMP concentrations using a cAMP standard curve prepared in KRBH buffer containing 0.1% (v/v) DMSO. The resulting cAMP curves were plotted as absolute cAMP concentrations (nM) over log (test compound concentration) and analyzed using the curve fitting program XLfit.

[0271] Parameters calculated to describe both the potency as well as the agonistic activity of each test compound on the receptors were:

[0272] EC50, a concentration resulting in a half-maximal elevation of cAMP levels, reflecting the potency of the test compound. The results are summarized in Table 2 and Table 2b. The most comprehensive data are summarized in table 2b.

TABLE 2

Average EC ₅₀ values on the GIP-R, GLP1-R and GCG-R respectively as compared to control peptides.			
Compound	GIP R (EC ₅₀ in nM)	GLP1 R (EC ₅₀ in nM)	GCG R (EC ₅₀ in nM)
hGIP	0.0038	—	—
Exendin-4	—	0.0043	—
glucagon	—	—	0.010*
1	0.38	0.033	0.013
2	0.35	0.089	0.046
3	0.13	0.015	0.022
5	0.17	0.0092	0.065
6	0.34	0.0095	0.018
7	0.42	0.031	0.086
8	0.20	0.015	0.042
9	0.056	0.0055	0.097

TABLE 2-continued

Average EC ₅₀ values on the GIP-R, GLP1-R and GCG-R respectively as compared to control peptides.			
Compound	GIP R (EC ₅₀ in nM)	GLP1 R (EC ₅₀ in nM)	GCG R (EC ₅₀ in nM)
10	0.24	0.012	0.10
11	0.28	0.020	0.11
12	0.084	0.012	0.076
13	0.083	0.0099	0.24
14	0.060	0.013	0.10
15	0.025	0.016	0.058
17	0.091	0.011	0.16
18	0.07	0.021	0.15
19	0.032	0.013	0.024
20	0.047	0.0094	0.057
21	0.18	0.014	0.10
22	0.18	0.028	0.76
23	0.13	0.11	0.14
24	0.10	0.091	0.28
25	0.25	0.28	0.30
26	0.070	0.030	0.040
27	0.12	0.16	0.070
28	0.054	0.058	0.16
29	0.060	0.050	0.15
30	0.15	0.022	0.024
31	0.087	0.013	0.011
32	0.044	0.015	0.15

TABLE 2b

Average EC ₅₀ values on the GIP-R, GLP1-R and GCG-R respectively as compared to control peptides.			
Compound	GIP R (EC ₅₀ in nM)	GLP1 R (EC ₅₀ in nM)	GCG R (EC ₅₀ in nM)
hGIP	0.003	>10	>10
Exendin-4	>10	0.004	>10
glucagon	>10	0.48	0.009
1	0.38	0.033	0.013
2	0.35	0.089	0.046
3	0.13	0.015	0.022
5	0.17	0.0092	0.065
6	0.32	0.0095	0.018
7	0.5	0.031	0.086
8	0.2	0.015	0.042
9	0.056	0.0055	0.097
10	0.2	0.012	0.1
11	0.25	0.02	0.11
12	0.084	0.012	0.076
13	0.083	0.0099	0.24
14	0.06	0.013	0.1
15	0.022	0.014	0.058
17	0.091	0.013	0.16
18	0.07	0.021	0.15
19	0.032	0.013	0.024
20	0.047	0.0093	0.057
21	0.18	0.015	0.1
22	0.18	0.03	0.76
23	0.13	0.11	0.14
24	0.097	0.11	0.28
25	0.19	0.28	0.3
26	0.07	0.03	0.04
27	0.099	0.16	0.07
28	0.054	0.058	0.16
29	0.064	0.05	0.15
30	0.15	0.022	0.024
31	0.087	0.013	0.011
32	0.04	0.015	0.15
33	0.0099	0.0093	0.58
34	0.0073	0.0066	0.11
35	0.01	0.012	0.011
37	0.018	NT	0.014

TABLE 2b-continued

Average EC ₅₀ values on the GIP-R, GLP1-R and GCG-R respectively as compared to control peptides.			
Compound	GIP R (EC ₅₀ in nM)	GLP1 R (EC ₅₀ in nM)	GCG R (EC ₅₀ in nM)
38	0.064	0.015	0.27
39	0.015	0.015	0.013
42	0.0098	0.015	0.032
43	0.0098	0.014	0.036
46	0.011	0.016	0.13
48	0.013	0.013	0.19
51	0.033	0.026	1.4
52	0.016	0.0096	1.8

NT: Not tested

[0273] It is anticipated that the exemplified compounds of the invention will have activities at the GCG-R that are close to that of native glucagon. At the same time, it is anticipated that they will exhibit strong GLP-1-R activation with EC₅₀ well below 1 nM. Likewise, it is anticipated that these peptides will also exhibit strong GIP-R activity with and EC₅₀ below or just above 1 nM.

Example 3

[0274] Pharmacokinetics of Selected Compounds in Mice

[0275] Method

[0276] C57BL/6J mice (males with a body weight of approximately 25 g) were given a single intravenous (i.v.) bolus of each peptide to be tested.

[0277] Following administration of the selected compounds (100 or 200 nmol/kg), blood samples were drawn 0.08, 0.17, 0.5, 1, 4, 8, 16 and 24 hours post-dose. Blood samples were drawn by sublingual bleeding. The dosing vehicle was a phosphate buffer containing mannitol (pH 7.5).

[0278] At each sampling time point, samples from two mice were drawn, i.e. 16 mice were included for each compound. The mice were euthanized immediately after blood sampling by cervical dislocation. Plasma samples were analyzed after solid phase extraction (SPE) or precipitation by liquid chromatography mass spectrometry (LC-MS/MS). Mean plasma concentrations were used for calculation of the pharmacokinetic parameters using the non-compartmental approach in Phoenix WinNonlin 6.3. Plasma terminal elimination half-life (T_{1/2}) was determined as $\ln(2)/\lambda_z$ where λ_z is the magnitude of the slope of the log linear regression of the log concentration versus time profile during the terminal phase. The results are summarized in Table 3

TABLE 3

Terminal elimination half-life (h) in mice following i.v. administration of selected compounds.	
Compound	T _{1/2} (h.)
28	7.8
32	4.1

SEQUENCE LISTING

```

<160> NUMBER OF SEQ ID NOS: 114

<210> SEQ ID NO 1
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 1

Tyr Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1           5           10           15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Arg Ala
20           25

<210> SEQ ID NO 2
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 2

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

```

-continued

1	5	10	15
---	---	----	----

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 3
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 3

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Arg Ala
20 25

<210> SEQ ID NO 4
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 4

Tyr Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Arg Ala
20 25

<210> SEQ ID NO 5
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 5

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Ser
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 6
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

-continued

<400> SEQUENCE: 6

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15

Lys Ala Ala Arg Asp Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 7

<211> LENGTH: 29

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 7

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Ala Leu Asp Ser
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 8

<211> LENGTH: 29

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 8

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Ser
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 9

<211> LENGTH: 29

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 9

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Glu
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 10

<211> LENGTH: 29

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

-continued

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 10

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Ser
1 5 10 15

Lys Ala Ala Lys Asp Phe Val Glu Trp Leu Leu Ser Ala
 20 25

<210> SEQ ID NO 11
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 11

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Ser
1 5 10 15

Lys Ala Ala His Asp Phe Val Asn Trp Leu Leu Ser Ala
 20 25

<210> SEQ ID NO 12
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 12

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Ser
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Arg Ala
 20 25

<210> SEQ ID NO 13
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 13

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Ser
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala Gly Pro Ser
 20 25 30

Ser Gly Ala Pro Pro Pro Ser
 35

-continued

<210> SEQ ID NO 14
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 14

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala
 20 25

<210> SEQ ID NO 15
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 15

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Lys Ala Gln Lys Glu Phe Val Glu Trp Leu Leu Ser Ala
 20 25

<210> SEQ ID NO 16
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 16

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Glu
1 5 10 15

Lys Ala Ala Lys Asp Phe Val Glu Trp Leu Leu Ser Ala
 20 25

<210> SEQ ID NO 17
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 17

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Ser
1 5 10 15

-continued

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 18
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 18

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 19
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 19

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Lys Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 20
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 20

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Ala Leu Asp Glu
1 5 10 15

Lys Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 21
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

-continued

<400> SEQUENCE: 21

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Lys
1 5 10 15

Lys Ala Gln Lys Glu Phe Val Glu Trp Leu Leu Ser Ala
 20 25

<210> SEQ ID NO 22
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 22

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Lys Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala
 20 25

<210> SEQ ID NO 23
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 23

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Lys Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala
 20 25

<210> SEQ ID NO 24
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (12)..(12)
<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 24

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Glu Lys
1 5 10 15

-continued

Lys Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 25
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 25

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15

Lys Ala Ala Lys Asp Phe Ile Glu Trp Leu Glu Ser Ala
20 25

<210> SEQ ID NO 26
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 26

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Ser
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Arg Ala
20 25

<210> SEQ ID NO 27
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 27

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Glu
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala
20 25

-continued

<210> SEQ ID NO 28
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 28

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Ser
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 29
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 29

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Glu
1 5 10 15

Lys Ala Ala Lys Asp Phe Val Glu Trp Leu Glu Ser Ala
20 25

<210> SEQ ID NO 30
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 30

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Glu
1 5 10 15

Lys Ala Ala Lys Asp Phe Ile Glu Trp Leu Glu Ser Ala
20 25

-continued

<210> SEQ ID NO 31
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(isoGlu-Hexadecanoyl)

<400> SEQUENCE: 31

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Lys Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala Gly Pro Ser
 20 25 30

Ser Gly Ala Pro Pro Pro Ser
 35

<210> SEQ ID NO 32
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys([17-carboxy-heptadecanoyl]-isoGlu-Peg3-
Peg3)

<400> SEQUENCE: 32

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Gly Pro Ser
 20 25 30

Ser Gly Ala Pro Pro Pro Ser
 35

<210> SEQ ID NO 33
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys([17-carboxy-heptadecanoyl]-isoGlu)

<400> SEQUENCE: 33

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Gly Pro Ser

-continued

20	25	30
----	----	----

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 34
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 34

Tyr	Xaa	Gln	Gly	Thr	Phe	Thr	Ser	Asp	Tyr	Ser	Ile	Tyr	Leu	Asp	Lys
1				5				10					15		

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 35
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(eicosanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 35

Tyr	Xaa	Gln	Gly	Thr	Phe	Thr	Ser	Asp	Tyr	Ser	Ile	Tyr	Leu	Asp	Lys
1				5				10					15		

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 36
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 36

-continued

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Lys Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 37
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 37

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Lys Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 38
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 38

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Glu
1 5 10 15

Lys Ala Ala Lys Glu Phe Ile Glu Trp Leu Glu Ser Ala
20 25

<210> SEQ ID NO 39
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)

-continued

<223> OTHER INFORMATION: Lys([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 39

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Glu
1 5 10 15

Lys Ala Ala Lys Glu Phe Ile Glu Trp Leu Glu Ser Ala
20 25

<210> SEQ ID NO 40

<211> LENGTH: 29

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Pro is Ac4c

<220> FEATURE:

<221> NAME/KEY: SITE

<222> LOCATION: (17)..(17)

<223> OTHER INFORMATION: Lys([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 40

Tyr Pro Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Glu
1 5 10 15

Lys Ala Ala Lys Glu Phe Ile Glu Trp Leu Glu Ser Ala
20 25

<210> SEQ ID NO 41

<211> LENGTH: 39

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Xaa is Aib

<220> FEATURE:

<221> NAME/KEY: SITE

<222> LOCATION: (17)..(17)

<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (29)..(29)

<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 41

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Asp Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Asn Trp Leu Val Ala Xaa Lys Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 42

<211> LENGTH: 39

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

-continued

<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Octadecanoyl-Dapa-Peg3-Peg3)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (29)..(29)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 42

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Asp Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Asn Trp Leu Val Ala Xaa Lys Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 43
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (29)..(29)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 43

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Asp Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Asn Trp Leu Val Ala Xaa Lys Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 44
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 44

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Lys
20 25 30

-continued

<210> SEQ ID NO 45
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 45

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Lys
20 25 30

<210> SEQ ID NO 46
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 46

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Lys
20 25 30

<210> SEQ ID NO 47
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 47

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Ile Ala Leu Glu Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Lys
20 25 30

<210> SEQ ID NO 48
<211> LENGTH: 30

-continued

<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Pro is Ac4c
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 48

Tyr Pro Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1 5 10 15
Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Lys
20 25 30

<210> SEQ ID NO 49
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 49

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15
Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Arg Ala
20 25

<210> SEQ ID NO 50
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 50

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15
Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Arg Ala
20 25

<210> SEQ ID NO 51
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Pro is Ac4c
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys([19-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 51

Tyr Pro Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Gly Pro Ser
 20 25 30

Ser Gly Ala Pro Pro Pro Ser
 35

<210> SEQ ID NO 52
<211> LENGTH: 40
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct: Glucagon-GLP-1-GIP triple
agonist compound - General formula I of PCT/EP2014/073971
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib, Gly, Ala, D-Ala, Ser, N-Me-Ser,
Ac3c, Ac4c or Ac5c
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (10)..(10)
<223> OTHER INFORMATION: Xaa is Tyr or Leu
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (12)..(12)
<223> OTHER INFORMATION: Xaa is Lys, Ile or Psi, wherein Psi is a
residue of Lys, Arg, Orn or Cys in which the side chain is
conjugated to a lipophilic substituent
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (13)..(13)
<223> OTHER INFORMATION: Xaa is Ala, Tyr or Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (15)..(15)
<223> OTHER INFORMATION: Xaa is Asp or Glu
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Xaa is Ser, Glu, Lys or Psi, wherein Psi is a
residue of Lys, Arg, Orn or Cys in which the side chain is
conjugated to a lipophilic substituent
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Lys or Psi, wherein Psi is a residue of
Lys, Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (19)..(19)
<223> OTHER INFORMATION: Xaa is Gln or Ala
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (20)..(20)
<223> OTHER INFORMATION: Xaa is Lys, His, Arg or Psi, wherein Psi is a
residue of Lys, Arg, Orn or Cys in which the side chain is
conjugated to a lipophilic substituent
<220> FEATURE:

-continued

```

<221> NAME/KEY: VARIANT
<222> LOCATION: (21)..(21)
<223> OTHER INFORMATION: Xaa is Ala, Asp or Glu
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (23)..(23)
<223> OTHER INFORMATION: Xaa is Val or Ile
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: Xaa is Asn, Glu or Psi, wherein Psi is a
      residue of Lys, Arg, Orn or Cys in which the side chain is
      conjugated to a lipophilic substituent
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (27)..(27)
<223> OTHER INFORMATION: Xaa is Leu, Glu or Val
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (28)..(28)
<223> OTHER INFORMATION: Xaa is Ala, Ser, Arg or Psi, wherein Psi is a
      residue of Lys, Arg, Orn or Cys in which the side chain is
      conjugated to a lipophilic substituent
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (29)..(29)
<223> OTHER INFORMATION: Xaa is Aib, Ala, Gln or Lys
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (30)..(30)
<223> OTHER INFORMATION: May be present or absent. If present, Xaa is
      Lys or Gly
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (31)..(40)
<223> OTHER INFORMATION: Xaa is: Gly Pro Ser Ser Gly Ala Pro Pro Pro
      Ser; Gly Pro Ser Ser Gly Ala Pro Pro Ser; Lys Pro Ser Ser Gly Ala
      Pro Pro Pro Ser; Lys Pro Ser Ser Gly Ala Pro Pro Ser; Pro Ser Ser
      Gly Ala Pro Pro Pro Ser; Pro Ser Ser Gly Ala Pro Pro Ser; or
      absent

<400> SEQUENCE: 52

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Xaa Xaa Leu Xaa Xaa
1           5           10           15

Xaa Ala Xaa Xaa Xaa Phe Xaa Xaa Trp Leu Xaa Xaa Xaa Xaa Xaa
      20           25           30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      35           40

<210> SEQ ID NO 53
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct: Y1 of SEQ ID NO: 52

<400> SEQUENCE: 53

Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser
1           5           10

<210> SEQ ID NO 54
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct: Y1 of SEQ ID NO: 52

<400> SEQUENCE: 54

Gly Pro Ser Ser Gly Ala Pro Pro Ser

```

-continued

1 5

<210> SEQ ID NO 55
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct: Y1 of SEQ ID NO: 52

<400> SEQUENCE: 55

Lys Pro Ser Ser Gly Ala Pro Pro Pro Ser
1 5 10

<210> SEQ ID NO 56
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct: Y1 of SEQ ID NO: 52

<400> SEQUENCE: 56

Lys Pro Ser Ser Gly Ala Pro Pro Ser
1 5

<210> SEQ ID NO 57
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct: Y1 of SEQ ID NO: 52

<400> SEQUENCE: 57

Pro Ser Ser Gly Ala Pro Pro Pro Ser
1 5

<210> SEQ ID NO 58
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct: Y1 of SEQ ID NO: 52

<400> SEQUENCE: 58

Pro Ser Ser Gly Ala Pro Pro Ser
1 5

<210> SEQ ID NO 59
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 59

Tyr Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Arg Ala
20 25

-continued

<210> SEQ ID NO 60
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 60

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Glu
1 5 10 15

Xaa Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 61
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 61

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Ser
1 5 10 15

Xaa Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 62
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 62

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser
1 5 10 15

Xaa Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala

-continued

20	25
----	----

<210> SEQ ID NO 63
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 63

Tyr	Xaa	Gln	Gly	Thr	Phe	Thr	Ser	Asp	Tyr	Ser	Ile	Tyr	Leu	Glu	Lys
1				5					10				15		

Xaa Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala

				20					25						
--	--	--	--	----	--	--	--	--	----	--	--	--	--	--	--

<210> SEQ ID NO 64
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 64

Tyr	Xaa	Gln	Gly	Thr	Phe	Thr	Ser	Asp	Tyr	Ser	Ile	Tyr	Leu	Glu	Xaa
1				5					10				15		

Lys Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala

				20					25						
--	--	--	--	----	--	--	--	--	----	--	--	--	--	--	--

<210> SEQ ID NO 65
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (12)..(12)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 65

Tyr	Xaa	Gln	Gly	Thr	Phe	Thr	Ser	Asp	Tyr	Ser	Xaa	Tyr	Leu	Glu	Lys
1				5					10				15		

-continued

Lys Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 66
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 66

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Ile Ala Leu Glu Lys
1 5 10 15

Xaa Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Lys
20 25 30

<210> SEQ ID NO 67
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 67

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu
1 5 10 15

Xaa Ala Ala Lys Asp Phe Ile Glu Trp Leu Glu Ser Ala
20 25

<210> SEQ ID NO 68
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 68

-continued

Tyr	Xaa	Gln	Gly	Thr	Phe	Thr	Ser	Asp	Tyr	Ser	Ile	Tyr	Leu	Asp	Glu
1				5					10					15	

Xaa	Ala	Ala	Lys	Asp	Phe	Val	Glu	Trp	Leu	Glu	Ser	Ala
			20					25				

<210> SEQ ID NO 69
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 69

Tyr	Xaa	Gln	Gly	Thr	Phe	Thr	Ser	Asp	Tyr	Ser	Ile	Tyr	Leu	Asp	Glu
1				5					10					15	

Xaa	Ala	Ala	Lys	Asp	Phe	Ile	Glu	Trp	Leu	Glu	Ser	Ala
			20					25				

<210> SEQ ID NO 70
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 70

Tyr	Xaa	Gln	Gly	Thr	Phe	Thr	Ser	Asp	Tyr	Ser	Ile	Tyr	Leu	Asp	Glu
1				5					10					15	

Xaa	Ala	Ala	Lys	Glu	Phe	Ile	Glu	Trp	Leu	Glu	Ser	Ala
			20					25				

<210> SEQ ID NO 71
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

-continued

<400> SEQUENCE: 71

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Ser
1 5 10 15
Xaa Ala Ala His Asp Phe Val Glu Trp Leu Leu Arg Ala
20 25

<210> SEQ ID NO 72

<211> LENGTH: 29

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Xaa is Aib

<220> FEATURE:

<221> NAME/KEY: VARIANT

<222> LOCATION: (17)..(17)

<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 72

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15
Xaa Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Arg Ala
20 25

<210> SEQ ID NO 73

<211> LENGTH: 29

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Xaa is Aib

<220> FEATURE:

<221> NAME/KEY: VARIANT

<222> LOCATION: (17)..(17)

<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (29)..(29)

<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 73

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Asp Lys
1 5 10 15
Xaa Ala Gln Arg Ala Phe Val Asn Trp Leu Val Ala Xaa
20 25

<210> SEQ ID NO 74

<211> LENGTH: 29

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Pro is Ac4c

<220> FEATURE:

-continued

<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 74

Tyr Pro Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Glu
1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Glu Ser Ala
20 25

<210> SEQ ID NO 75
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Pro is Ac4c
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 75

Tyr Pro Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1 5 10 15

Xaa Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 76
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Pro is Ac4c
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 76

Tyr Pro Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys
1 5 10 15

Xaa Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 77
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)

-continued

<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 77

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1 5 10 15

Xaa Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 78
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 78

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Ser
1 5 10 15

Xaa Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 79
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 79

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Xaa Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 80

-continued

<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 80

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys
1 5 10 15

Xaa Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 81
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 81

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1 5 10 15

Xaa Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Lys
20 25 30

<210> SEQ ID NO 82
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (29)..(29)
<223> OTHER INFORMATION: Xaa is Aib
<400> SEQUENCE: 82

-continued

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Asp Lys
1 5 10 15

Xaa Ala Gln Arg Ala Phe Val Asn Trp Leu Val Ala Xaa Lys Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 83
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Pro is Ac4c
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 83

Tyr Pro Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1 5 10 15

Xaa Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Lys
20 25 30

<210> SEQ ID NO 84
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Pro is Ac4c
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
Arg, Orn or Cys in which the side chain is conjugated to a
lipophilic substituent

<400> SEQUENCE: 84

Tyr Pro Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys
1 5 10 15

Xaa Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 85
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib

-continued

<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 85

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Ser
1 5 10 15

Lys Ala Ala His Asp Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 86
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 86

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Lys Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 87
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 87

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Lys Ala Ala Lys Glu Phe Val Glu Trp Leu Leu Ser Ala
20 25

<210> SEQ ID NO 88
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)

-continued

<223> OTHER INFORMATION: Lys([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 88

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 89

<211> LENGTH: 29

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Xaa is Aib

<220> FEATURE:

<221> NAME/KEY: SITE

<222> LOCATION: (17)..(17)

<223> OTHER INFORMATION: Lys([17-carboxy-heptadecanoyl]-isoGlu)

<400> SEQUENCE: 89

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 90

<211> LENGTH: 29

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Xaa is Aib

<220> FEATURE:

<221> NAME/KEY: SITE

<222> LOCATION: (17)..(17)

<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 90

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 91

<211> LENGTH: 28

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Xaa is Aib

<220> FEATURE:

<221> NAME/KEY: SITE

<222> LOCATION: (16)..(16)

<223> OTHER INFORMATION: Lys(eicosanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 91

-continued

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys
1 5 10 15

Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 92
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 92

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 93
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 93

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 94
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 94

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1 5 10 15

-continued

Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 95
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 95

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Ile Ala Leu Glu Lys
1 5 10 15

Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 96
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 96

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Arg Ala
20 25

<210> SEQ ID NO 97
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 97

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys
1 5 10 15

Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Arg Ala
20 25

-continued

<210> SEQ ID NO 98
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (28)..(28)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 98

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Asp Lys
1 5 10 15

Ala Gln Arg Ala Phe Val Asn Trp Leu Val Ala Xaa
 20 25

<210> SEQ ID NO 99
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys(Octadecanoyl-Dapa-Peg3-Peg3)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (28)..(28)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 99

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Asp Lys
1 5 10 15

Ala Gln Arg Ala Phe Val Asn Trp Leu Val Ala Xaa
 20 25

<210> SEQ ID NO 100
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Lys([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (29)..(29)
<223> OTHER INFORMATION: Xaa is Aib

-continued

<400> SEQUENCE: 100

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Asp Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Asn Trp Leu Val Ala Xaa
20 25

<210> SEQ ID NO 101

<211> LENGTH: 28

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Pro is Ac4c

<220> FEATURE:

<221> NAME/KEY: SITE

<222> LOCATION: (16)..(16)

<223> OTHER INFORMATION: Lys([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 101

Tyr Pro Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1 5 10 15

Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 102

<211> LENGTH: 29

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Pro is Ac4c

<220> FEATURE:

<221> NAME/KEY: SITE

<222> LOCATION: (17)..(17)

<223> OTHER INFORMATION: Lys(19-carboxy-heptadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 102

Tyr Pro Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Asp Lys
1 5 10 15

Lys Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
20 25

<210> SEQ ID NO 103

<211> LENGTH: 39

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: Xaa is Aib

<220> FEATURE:

<221> NAME/KEY: SITE

<222> LOCATION: (17)..(17)

<223> OTHER INFORMATION: Lys(Hexadecanoyl-isoGlu)

<400> SEQUENCE: 103

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Tyr Leu Glu Lys

-continued

1	5	10	15
Lys	Ala	Ala	Lys
	20	25	30
Glu	Phe	Val	Glu
Trp	Leu	Leu	Ser
Ala	Gly	Pro	Ser
Ser	Gly	Ala	Pro
Pro	Pro	Pro	Ser
35			

<210> SEQ ID NO 104
<211> LENGTH: 38
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys(eicosanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 104

Tyr	Xaa	Gln	Gly	Thr	Phe	Thr	Ser	Asp	Tyr	Ser	Ile	Tyr	Leu	Asp	Lys
1		5					10						15		
Ala	Gln	Arg	Ala	Phe	Val	Glu	Trp	Leu	Leu	Ala	Gln	Gly	Pro	Ser	Ser
	20						25						30		
Gly	Ala	Pro	Pro	Pro	Ser										
35															

<210> SEQ ID NO 105
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 105

Tyr	Xaa	Gln	Gly	Thr	Phe	Thr	Ser	Asp	Tyr	Ser	Ile	Ala	Leu	Glu	Lys
1		5					10						15		
Ala	Gln	Arg	Ala	Phe	Val	Glu	Trp	Leu	Leu	Ala	Gln	Lys			
	20						25								

<210> SEQ ID NO 106
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)

<400> SEQUENCE: 106

-continued

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Ile Ala Leu Glu Lys
1 5 10 15

Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln Lys
20 25

<210> SEQ ID NO 107
<211> LENGTH: 38
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys(Octadecanoyl-isoGlu-Peg3-Peg3)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (28)..(28)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 107

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Asp Lys
1 5 10 15

Ala Gln Arg Ala Phe Val Asn Trp Leu Val Ala Xaa Lys Pro Ser Ser
20 25 30

Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 108
<211> LENGTH: 38
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys(Octadecanoyl-Dapa-Peg3-Peg3)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (28)..(28)
<223> OTHER INFORMATION: Xaa is Aib

<400> SEQUENCE: 108

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Asp Lys
1 5 10 15

Ala Gln Arg Ala Phe Val Asn Trp Leu Val Ala Xaa Lys Pro Ser Ser
20 25 30

Gly Ala Pro Pro Pro Ser
35

<210> SEQ ID NO 109
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

-continued

```

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Pro is Ac4c
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (16)..(16)
<223> OTHER INFORMATION: Lys([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3)

```

```

<400> SEQUENCE: 109

```

```

Tyr Pro Gln Gly Thr Phe Thr Ser Asp Tyr Ser Ile Ala Leu Glu Lys
1           5           10          15

Ala Gln Arg Ala Phe Val Glu Trp Leu Ala Gln Lys
          20           25

```

```

<210> SEQ ID NO 110
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa is Aib
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)..(17)
<223> OTHER INFORMATION: Xaa is Psi, wherein Psi is a residue of Lys,
        Arg, Orn or Cys in which the side chain is conjugated to a
        lipophilic substituent

```

```

<400> SEQUENCE: 110

```

```

Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Ile Ala Leu Glu Lys
1           5           10          15

Xaa Ala Gln Arg Ala Phe Val Glu Trp Leu Leu Ala Gln
          20           25

```

```

<210> SEQ ID NO 111
<211> LENGTH: 466
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 111

```

```

Met Thr Thr Ser Pro Ile Leu Gln Leu Leu Arg Leu Ser Leu Cys
1           5           10          15

Gly Leu Leu Leu Gln Arg Ala Glu Thr Gly Ser Lys Gly Gln Thr Ala
          20           25          30

Gly Glu Leu Tyr Gln Arg Trp Glu Arg Tyr Arg Arg Glu Cys Gln Glu
          35           40          45

Thr Leu Ala Ala Ala Glu Pro Pro Ser Gly Leu Ala Cys Asn Gly Ser
          50           55          60

Phe Asp Met Tyr Val Cys Trp Asp Tyr Ala Ala Pro Asn Ala Thr Ala
          65           70          75          80

Arg Ala Ser Cys Pro Trp Tyr Leu Pro Trp His His His Val Ala Ala
          85           90          95

Gly Phe Val Leu Arg Gln Cys Gly Ser Asp Gly Gln Trp Gly Leu Trp
          100          105          110

Arg Asp His Thr Gln Cys Glu Asn Pro Glu Lys Asn Glu Ala Phe Leu
          115          120          125

Asp Gln Arg Leu Ile Leu Glu Arg Leu Gln Val Met Tyr Thr Val Gly

```

-continued

130	135	140
Tyr Ser Leu Ser Leu Ala Thr Leu Leu Leu Ala Leu Leu Ile Leu Ser		
145	150	155 160
Leu Phe Arg Arg Leu His Cys Thr Arg Asn Tyr Ile His Ile Asn Leu		
	165	170 175
Phe Thr Ser Phe Met Leu Arg Ala Ala Ala Ile Leu Ser Arg Asp Arg		
	180	185 190
Leu Leu Pro Arg Pro Gly Pro Tyr Leu Gly Asp Gln Ala Leu Ala Leu		
	195	200 205
Trp Asn Gln Ala Leu Ala Ala Cys Arg Thr Ala Gln Ile Val Thr Gln		
	210	215 220
Tyr Cys Val Gly Ala Asn Tyr Thr Trp Leu Leu Val Glu Gly Val Tyr		
	225	230 235 240
Leu His Ser Leu Leu Val Leu Val Gly Gly Ser Glu Glu Gly His Phe		
	245	250 255
Arg Tyr Tyr Leu Leu Leu Gly Trp Gly Ala Pro Ala Leu Phe Val Ile		
	260	265 270
Pro Trp Val Ile Val Arg Tyr Leu Tyr Glu Asn Thr Gln Cys Trp Glu		
	275	280 285
Arg Asn Glu Val Lys Ala Ile Trp Trp Ile Ile Arg Thr Pro Ile Leu		
	290	295 300
Met Thr Ile Leu Ile Asn Phe Leu Ile Phe Ile Arg Ile Leu Gly Ile		
	305	310 315 320
Leu Leu Ser Lys Leu Arg Thr Arg Gln Met Arg Cys Arg Asp Tyr Arg		
	325	330 335
Leu Arg Leu Ala Arg Ser Thr Leu Thr Leu Val Pro Leu Leu Gly Val		
	340	345 350
His Glu Val Val Phe Ala Pro Val Thr Glu Glu Gln Ala Arg Gly Ala		
	355	360 365
Leu Arg Phe Ala Lys Leu Gly Phe Glu Ile Phe Leu Ser Ser Phe Gln		
	370	375 380
Gly Phe Leu Val Ser Val Leu Tyr Cys Phe Ile Asn Lys Glu Val Gln		
	385	390 395 400
Ser Glu Ile Arg Arg Gly Trp His His Cys Arg Leu Arg Arg Ser Leu		
	405	410 415
Gly Glu Glu Gln Arg Gln Leu Pro Glu Arg Ala Phe Arg Ala Leu Pro		
	420	425 430
Ser Gly Ser Gly Pro Gly Glu Val Pro Thr Ser Arg Gly Leu Ser Ser		
	435	440 445
Gly Thr Leu Pro Gly Pro Gly Asn Glu Ala Ser Arg Glu Leu Glu Ser		
	450	455 460
Tyr Cys		
465		

<210> SEQ ID NO 112

<211> LENGTH: 463

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 112

Met Ala Gly Ala Pro Gly Pro Leu Arg Leu Ala Leu Leu Leu Gly
1 5 10 15

-continued

Met	Val	Gly	Arg	Ala	Gly	Pro	Arg	Pro	Gln	Gly	Ala	Thr	Val	Ser	Leu
			20					25					30		
Trp	Glu	Thr	Val	Gln	Lys	Trp	Arg	Glu	Tyr	Arg	Arg	Gln	Cys	Gln	Arg
	35					40					45				
Ser	Leu	Thr	Glu	Asp	Pro	Pro	Pro	Ala	Thr	Asp	Leu	Phe	Cys	Asn	Arg
	50				55						60				
Thr	Phe	Asp	Glu	Tyr	Ala	Cys	Trp	Pro	Asp	Gly	Glu	Pro	Gly	Ser	Phe
65					70					75					80
Val	Asn	Val	Ser	Cys	Pro	Trp	Tyr	Leu	Pro	Trp	Ala	Ser	Ser	Val	Pro
			85					90						95	
Gln	Gly	His	Val	Tyr	Arg	Phe	Cys	Thr	Ala	Glu	Gly	Leu	Trp	Leu	Gln
		100						105					110		
Lys	Asp	Asn	Ser	Ser	Leu	Pro	Trp	Arg	Asp	Leu	Ser	Glu	Cys	Glu	Glu
		115					120					125			
Ser	Lys	Arg	Gly	Glu	Arg	Ser	Ser	Pro	Glu	Glu	Gln	Leu	Leu	Phe	Leu
	130					135					140				
Tyr	Ile	Ile	Tyr	Thr	Val	Gly	Tyr	Ala	Leu	Ser	Phe	Ser	Ala	Leu	Val
145					150				155						160
Ile	Ala	Ser	Ala	Ile	Leu	Leu	Gly	Phe	Arg	His	Leu	His	Cys	Thr	Arg
			165					170						175	
Asn	Tyr	Ile	His	Leu	Asn	Leu	Phe	Ala	Ser	Phe	Ile	Leu	Arg	Ala	Leu
		180					185						190		
Ser	Val	Phe	Ile	Lys	Asp	Ala	Ala	Leu	Lys	Trp	Met	Tyr	Ser	Thr	Ala
		195					200					205			
Ala	Gln	Gln	His	Gln	Trp	Asp	Gly	Leu	Leu	Ser	Tyr	Gln	Asp	Ser	Leu
	210					215					220				
Ser	Cys	Arg	Leu	Val	Phe	Leu	Leu	Met	Gln	Tyr	Cys	Val	Ala	Ala	Asn
225					230					235					240
Tyr	Tyr	Trp	Leu	Leu	Val	Glu	Gly	Val	Tyr	Leu	Tyr	Thr	Leu	Leu	Ala
			245					250						255	
Phe	Ser	Val	Leu	Ser	Glu	Gln	Trp	Ile	Phe	Arg	Leu	Tyr	Val	Ser	Ile
		260					265						270		
Gly	Trp	Gly	Val	Pro	Leu	Leu	Phe	Val	Val	Pro	Trp	Gly	Ile	Val	Lys
		275					280					285			
Tyr	Leu	Tyr	Glu	Asp	Glu	Gly	Cys	Trp	Thr	Arg	Asn	Ser	Asn	Met	Asn
	290					295					300				
Tyr	Trp	Leu	Ile	Ile	Arg	Leu	Pro	Ile	Leu	Phe	Ala	Ile	Gly	Val	Asn
305					310					315					320
Phe	Leu	Ile	Phe	Val	Arg	Val	Ile	Cys	Ile	Val	Val	Ser	Lys	Leu	Lys
			325					330						335	
Ala	Asn	Leu	Met	Cys	Lys	Thr	Asp	Ile	Lys	Cys	Arg	Leu	Ala	Lys	Ser
		340					345						350		
Thr	Leu	Thr	Leu	Ile	Pro	Leu	Leu	Gly	Thr	His	Glu	Val	Ile	Phe	Ala
	355					360						365			
Phe	Val	Met	Asp	Glu	His	Ala	Arg	Gly	Thr	Leu	Arg	Phe	Ile	Lys	Leu
	370					375					380				
Phe	Thr	Glu	Leu	Ser	Phe	Thr	Ser	Phe	Gln	Gly	Leu	Met	Val	Ala	Ile
385					390					395					400
Leu	Tyr	Cys	Phe	Val	Asn	Asn	Glu	Val	Gln	Leu	Glu	Phe	Arg	Lys	Ser
			405					410						415	
Trp	Glu	Arg	Trp	Arg	Leu	Glu	His	Leu	His	Ile	Gln	Arg	Asp	Ser	Ser

-continued

420				425				430							
Met	Lys	Pro	Leu	Lys	Cys	Pro	Thr	Ser	Ser	Leu	Ser	Ser	Gly	Ala	Thr
	435						440						445		
Ala	Gly	Ser	Ser	Met	Tyr	Thr	Ala	Thr	Cys	Gln	Ala	Ser	Cys	Ser	
	450					455					460				
<210> SEQ ID NO 113															
<211> LENGTH: 477															
<212> TYPE: PRT															
<213> ORGANISM: Homo sapiens															
<400> SEQUENCE: 113															
Met	Pro	Pro	Cys	Gln	Pro	Gln	Arg	Pro	Leu	Leu	Leu	Leu	Leu	Leu	Leu
1			5						10					15	
Leu	Ala	Cys	Gln	Pro	Gln	Val	Pro	Ser	Ala	Gln	Val	Met	Asp	Phe	Leu
		20						25					30		
Phe	Glu	Lys	Trp	Lys	Leu	Tyr	Gly	Asp	Gln	Cys	His	His	Asn	Leu	Ser
		35					40						45		
Leu	Leu	Pro	Pro	Pro	Thr	Glu	Leu	Val	Cys	Asn	Arg	Thr	Phe	Asp	Lys
		50				55					60				
Tyr	Ser	Cys	Trp	Pro	Asp	Thr	Pro	Ala	Asn	Thr	Thr	Ala	Asn	Ile	Ser
					70					75				80	
Cys	Pro	Trp	Tyr	Leu	Pro	Trp	His	His	Lys	Val	Gln	His	Arg	Phe	Val
			85						90					95	
Phe	Lys	Arg	Cys	Gly	Pro	Asp	Gly	Gln	Trp	Val	Arg	Gly	Pro	Arg	Gly
			100						105				110		
Gln	Pro	Trp	Arg	Asp	Ala	Ser	Gln	Cys	Gln	Met	Asp	Gly	Glu	Glu	Ile
			115				120						125		
Glu	Val	Gln	Lys	Glu	Val	Ala	Lys	Met	Tyr	Ser	Ser	Phe	Gln	Val	Met
		130				135					140				
Tyr	Thr	Val	Gly	Tyr	Ser	Leu	Ser	Leu	Gly	Ala	Leu	Leu	Leu	Ala	Leu
					150					155					160
Ala	Ile	Leu	Gly	Gly	Leu	Ser	Lys	Leu	His	Cys	Thr	Arg	Asn	Ala	Ile
			165						170					175	
His	Ala	Asn	Leu	Phe	Ala	Ser	Phe	Val	Leu	Lys	Ala	Ser	Ser	Val	Leu
			180						185					190	
Val	Ile	Asp	Gly	Leu	Leu	Arg	Thr	Arg	Tyr	Ser	Gln	Lys	Ile	Gly	Asp
		195					200						205		
Asp	Leu	Ser	Val	Ser	Thr	Trp	Leu	Ser	Asp	Gly	Ala	Val	Ala	Gly	Cys
		210				215					220				
Arg	Val	Ala	Ala	Val	Phe	Met	Gln	Tyr	Gly	Ile	Val	Ala	Asn	Tyr	Cys
		225				230				235				240	
Trp	Leu	Leu	Val	Glu	Gly	Leu	Tyr	Leu	His	Asn	Leu	Leu	Gly	Leu	Ala
			245						250					255	
Thr	Leu	Pro	Glu	Arg	Ser	Phe	Phe	Ser	Leu	Tyr	Leu	Gly	Ile	Gly	Trp
			260						265				270		
Gly	Ala	Pro	Met	Leu	Phe	Val	Val	Pro	Trp	Ala	Val	Val	Lys	Cys	Leu
			275				280						285		
Phe	Glu	Asn	Val	Gln	Cys	Trp	Thr	Ser	Asn	Asp	Asn	Met	Gly	Phe	Trp
		290				295					300				
Trp	Ile	Leu	Arg	Phe	Pro	Val	Phe	Leu	Ala	Ile	Leu	Ile	Asn	Phe	Phe
			305			310				315				320	

-continued

```

Ile Phe Val Arg Ile Val Gln Leu Leu Val Ala Lys Leu Arg Ala Arg
      325                      330                      335

Gln Met His His Thr Asp Tyr Lys Phe Arg Leu Ala Lys Ser Thr Leu
      340                      345                      350

Thr Leu Ile Pro Leu Leu Gly Val His Glu Val Val Phe Ala Phe Val
      355                      360                      365

Thr Asp Glu His Ala Gln Gly Thr Leu Arg Ser Ala Lys Leu Phe Phe
      370                      375                      380

Asp Leu Phe Leu Ser Ser Phe Gln Gly Leu Leu Val Ala Val Leu Tyr
      385                      390                      395                      400

Cys Phe Leu Asn Lys Glu Val Gln Ser Glu Leu Arg Arg Arg Trp His
      405                      410                      415

Arg Trp Arg Leu Gly Lys Val Leu Trp Glu Glu Arg Asn Thr Ser Asn
      420                      425                      430

His Arg Ala Ser Ser Ser Pro Gly His Gly Pro Pro Ser Lys Glu Leu
      435                      440                      445

Gln Phe Gly Arg Gly Gly Gly Ser Gln Asp Ser Ser Ala Glu Thr Pro
      450                      455                      460

Leu Ala Gly Gly Leu Pro Arg Leu Ala Glu Ser Pro Phe
      465                      470                      475

<210> SEQ ID NO 114
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic linker

<400> SEQUENCE: 114

Gly Ser Gly Ser Gly Gly
1          5

```

1. A glucagon-GLP-1-GIP triple agonist compound having the general formula I:

(I)

R¹-Tyr-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-Leu-X15-X16-X17-Ala-X19-X20-X21-Phe-X23-X24-Trp-Leu-X27-X28-X29-X30-Y1-R²

wherein

R¹ is H—, C₁₋₄ alkyl, acetyl, formyl, benzoyl, trifluoroacetyl or pGlu;

X2 is Aib, Gly, Ala, D-Ala, Ser, N-Me-Ser, Ac3c, Ac4c or Ac5c;

X10 is Tyr or Leu;

X12 is Lys, Ile or ψ;

X13 is Ala, Tyr or Aib;

X15 is Asp or Glu;

X16 is Ser, Glu, Lys or ψ;

X17 is Lys or ψ;

X19 is Gln or Ala;

X20 is Lys, His, Arg or ψ;

X21 is Ala, Asp or Glu;

X23 is Val or Ile;

X24 is Asn, Glu or ψ;

X27 is Leu, Glu or Val;

X28 is Ala, Ser, Arg or ψ;

X29 is Aib, Ala, Gln or Lys;

X30 is Lys, Gly, or is absent;

Y1 is Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser, Lys-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, Lys-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser, Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser, or is absent;

ψ is a residue of Lys, Arg, Orn or Cys in which the side chain is conjugated to a lipophilic substituent;

and

R² is —NH₂ or —OH;

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 wherein W is present at one of positions X12, X16 or X17.

3. A compound according to claim 1 or claim 2 wherein the compound contains only one residue ψ.

4. A compound according to any one of claims 1 to 3 wherein the compound possesses one or more of the following sets of residues:

K12 and K12 and Y13; I12 and Y13; K12 and A13; I12 and A13; or ψ 12 and Y13;

D15 and S16; D15 and E16; E15 and K16; D15 and ψ 16; E15 and S16; or E15 and ψ 16;

A19, H20, and D21; A19, K20, and D21; A19, R20, and D21; Q19, K20, and E21; A19, K20, and E21; or Q19, R20, and A21;

I23 and E24; V23 and E24; or V23 and N24;

L27, R28, and A29; L27, S28, and A29; L27, A28, and Q29; E27, S28, and A29; or V27, A28, and Aib29;

E15 and K17;

E15 and ψ 17;

E15, ψ 17, and Q19;

Q19 and E24;

E16, ψ 17, and Q19; or

K16, ψ 17, and Q19.

5. A compound according to claim 4 further comprising:

Aib2, Ser2 or Ac4c2; and/or

Tyr10; or

Leu10.

6. A compound according to any one of the preceding claims wherein positions 1 to 29 have the sequence:

YSQGTFTSDYSKYLDKAAHDFVEWLLRA;

YSQGTFTSDYSKYLD Ψ KAAHDFVEWLLRA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

-continued

Y-Aib-QGTFTSDYSKYLEKKAQKEFVEWLLSA;

Y-Aib-QGTFTSDYSIYLEKKAQKEFVEWLLSA;

Y-Aib-QGTFTSDYSKALDEKAAKEFVEWLLSA;

Y-Aib-QGTFTSDYSIYLEK Ψ AAKEFVEWLLSA;

Y-Aib-QGTFTSDYSIYLE Ψ KAAKEFVEWLLSA;

Y-Aib-QGTFTSDYS Ψ YLEKKAQKEFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVNWLLSA;

Y-Aib-QGTFTSDLSIALEK Ψ AQRAFVEWLLAQK;

Y-Aib-QGTFTSDYSKYLDE Ψ AAKDFIEWLESA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSKYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLEK Ψ AQRAFVEWLLSA;

Y-Aib-QGTFTSDYSIALDK Ψ AQRAFVNWLLA-Aib;

Y-Ac4c-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Ac4c-QGTFTSDYSIALEK Ψ AQRAFVEWLLAQ;

or

Y-Ac4c-QGTFTSDYSIYLDKAAHDFVEWLLAQ.

7. A compound according to claim 1 which differs at up to 4 positions from any of the sequences listed in claim 6.

8. A compound according to claim 7 which differs at up to 4 positions from one of the sequences:

Y-Aib-QGTFTSDYSIYLEK Ψ AAKEFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

and

Y-Aib-QGTFTSDYSIALEK Ψ AQRAFVEWLLAQ.

9. A compound according to claim 1 wherein the peptide backbone of Formula I has the sequence:

YSQGTFTSDYSKYLDKAAHDFVEWLLRA;

YSQGTFTSDYSKYLD Ψ KAAHDFVEWLLRA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSAGPSSGAPPPS;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLSA;

-continued

Y-Aib-QGTFTSDYSIYLDSPAAHDFVEWLLSAGPSSGAPPPS;
 Y-Aib-QGTFTSDYSKYLDSPAAHDFVEWLLSA;
 Y-Aib-QGTFTSDYSKALDSKAAHDFVEWLLSA;
 Y-Aib-QGTFTSDYSKYLESKAAHDFVEWLLSA;
 Y-Aib-QGTFTSDYSIYLDSKAAKDFVEWLLSA;
 Y-Aib-QGTFTSDYSIYLDKAAKDFVEWLLSA;
 Y-Aib-QGTFTSDYSKYLDKAAKDFVEWLLSA;
 Y-Aib-QGTFTSDYSIYLEKKAQKEFVEWLLSA;
 Y-Aib-QGTFTSDYSKYLEKKAQKEFVEWLLSA;
 Y-Aib-QGTFTSDYSIYLEKKAKEFVEWLLSA;
 Y-Aib-QGTFTSDYSKALDEKAAKEFVEWLLSA;
 Y-Aib-QGTFTSDYSIYLEKPSAAKEFVEWLLSA;
 Y-Aib-QGTFTSDYSIYLEKPSAAKEFVEWLLSA;
 Y-Aib-QGTFTSDYSIYLDKPSAQAQRAVFWLLAQGPSSGAPPPS;
 Y-Aib-QGTFTSDYSIYLDKPSAQAQRAVFWLLAQK;
 Y-Aib-QGTFTSDLSIALEKPSAQAQRAVFWLLAQK;
 Y-Aib-QGTFTSDYSKYLDSPAAKDFIEWLESA;
 Y-Aib-QGTFTSDYSIYLDSPAAKDFIEWLESA;
 Y-Aib-QGTFTSDYSIYLDSPAAKDFIEWLESA;
 Y-Aib-QGTFTSDYSIYLDSPAAKEFIEWLESA;
 Y-Aib-QGTFTSDYSKYLDKAAHDFVEWLLRA;
 Y-Aib-QGTFTSDYSIYLDKAAHDFVEWLLRA;
 Y-Aib-QGTFTSDYSIYLDSPAAHDFVEWLLRA;
 Y-Aib-QGTFTSDYSIYLEKPSAQAQRAVFWLLRA;
 Y-Aib-QGTFTSDYSIALDKPSAQAQRAVFWNLVA-Aib-KPSSGAPPPS;
 Y-Ac4c-QGTFTSDYSIYLDSPAAKEFIEWLESA;
 Y-Ac4c-QGTFTSDYSIALEKPSAQAQRAVFWLLAQK;
 or
 Y-Ac4c-QGTFTSDYSIYLDKPSAQAQRAVFWLLAQGPSSGAPPPS.

10. A compound according to claim 1 wherein the peptide backbone of Formula I has a sequence which differs at up to 5 positions from one of the sequences shown in in claim 10.

11. A compound according to claim 10 which differs at up to 5 positions from one of the sequences:

Y-Aib-QGTFTSDYSIYLEKPSAAKEFVEWLLSAGPSSGAPPPS;
 Y-Aib-QGTFTSDYSIYLDSPAAHDFVEWLLSA;

-continued

or

Y-Aib-QGTFTSDYSIALEKPSAQAQRAVFWLLAQK.

12. A compound according to any one of the preceding claims wherein W is a residue of Lys in which the side chain is conjugated to a lipophilic substituent.

13. A compound according to any one of the preceding claims wherein the lipophilic substituent has the formula $-Z^1$ or $-Z^2-Z^1$ wherein:


$-Z^1$ is a fatty chain having at a terminus a connection $-X-$ to ψ or to Z^2 ;

wherein

$-X-$ is a bond, $-CO-$, $-SO-$, or $-SO_2-$;

and, optionally, Z^1 has a polar group at the end of the chain distal from connection $-X-$, said polar group comprising a carboxylic acid or a carboxylic acid bioisostere, a phosphonic acid, or a sulfonic acid group;

and wherein $-Z^2-$, if present, is a spacer of formula:



connecting Z^1 to ψ ;

wherein:

each Y is independently $-NH-$, $-NR-$, $-S$ or $-O-$, where R is alkyl, a protecting group or forms a linkage to another part of the spacer Z^2 ;

each X is independently a bond, $CO-$, $SO-$, or SO_2- ;

with the proviso that when Y is $-S-$, the X to which it is bound is a bond;

each V is independently a bivalent organic moiety linking Y and X;

and n is 1-10.

14. A compound according to claim 13 wherein the lipophilic substituent has the formula $-Z^2-Z^1$.

15. A compound according to claim 12 or claim 14 wherein Z^1 is A-B-alkylene-CO— wherein A is H or $-COOH$ and B is a bond.

16. A compound according to claim 15 wherein Z^1 is A-B- C_{16-20} alkylene-(CO)—.

17. A compound according to any one of claims 13 to 16 wherein Z^1 is:

hexadecanoyl; 17-carboxy-heptadecanoyl $[HOOC-(CH_2)_{16}-(CO)-]$;




19-carboxy-nonadecanoyl $[HOOC-(CH_2)_{18}-(CO)-]$;

Octadecanoyl $[H_3C-(CH_2)_{16}-(CO)-]$; or




Eicosanoyl $[H_3C-(CH_2)_{18}-(CO)-]$.

18. A compound according to any one of claims 13 to 17 wherein Z^2 comprises a residue selected from isoGlu or Dapa.

19. A compound according to claim 13 wherein $-Z^1$ or $-Z^2-Z^1$ is:




-continued



-continued

(vii)



Hexadecanoyl-isoGlu

20. A compound according to claim 1 wherein positions 1 to 29 have the sequence:

YSQGTFTSDYSKYLD-K (Hexadecanoyl-isoGlu) - KAAHDFVEWLLRA;

Y-Aib-QGTFTSDYSIYLDE-K (Hexadecanoyl-isoGlu) - AAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDK-K (Hexadecanoyl-isoGlu) - AAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDK-K (Hexadecanoyl-isoGlu) - AAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLEK-K (Hexadecanoyl-isoGlu) - AAKEFVEWLLSA;

Y-Aib-QGTFTSDYSIYLE-K (Hexadecanoyl-isoGlu) - KAAKEFVEWLLSA;

Y-Aib-QGTFTSDYS-K (Hexadecanoyl-isoGlu) - YLEKKAKEFVEWLLSA;

Y-Aib-QGTFTSDYSIYLEK-K (Hexadecanoyl-isoGlu) - AAKEFVEWLLSA;

Y-Aib-QGTFTSDYSIYLEK-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AAKEFVEWLLSA;

Y-Aib-QGTFTSDYSIYLEK-K ([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3) - AAKEFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDK-K ([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQ;

Y-Aib-QGTFTSDYSIYLDK-K ([17-carboxy-heptadecanoyl]-isoGlu) - AQRAFVEWLLAQ;

Y-Aib-QGTFTSDYSIYLDK-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQ;

Y-Aib-QGTFTSDYSIYLD-K (eicosanoyl-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQ;

Y-Aib-QGTFTSDYSIALEK-K ([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQ;

Y-Aib-QGTFTSDYSIALEK-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQ;

Y-Aib-QGTFTSDYSIALE-K ([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQ;

Y-Aib-QGTFTSDLSIALE-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQ;

Y-Aib-QGTFTSDYSKYLDE-K (Hexadecanoyl-isoGlu) - AAKDFIEWLESA;

-continued

Y-Aib-QGTFTSDYSIYLDE-K (Hexadecanoyl-isoGlu) - AAKDFIEWLESA;

Y-Aib-QGTFTSDYSIYLDE-K (Hexadecanoyl-isoGlu) - AAKDFIEWLESA;

Y-Aib-QGTFTSDYSIYLDE-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AAKEFIEWLESA;

Y-Aib-QGTFTSDYSIYLDE-K ([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3) - AAKEFIEWLESA;

Y-Aib-QGTFTSDYSIYLDK-K (Hexadecanoyl-isoGlu) - AAHDFVEWLLRA;

Y-Aib-QGTFTSDYSIYLE-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AQRAFVEWLLRA;

Y-Aib-QGTFTSDYSIYLE-K ([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3) - AQRAFVEWLLRA;

Y-Aib-QGTFTSDYSIALD-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AQRAFVNWLLA-Aib;

Y-Aib-QGTFTSDYSIALD-K (Octadecanoyl-Dapa-Peg3-Peg3) - AQRAFVNWLLA-Aib;

Y-Aib-QGTFTSDYSIALDK-K ([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3) - AQRAFVNWLLA-Aib;

Y-Ac4c-QGTFTSDYSIYLDE-K ([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3) - AAKEFIEWLESA;

Y-Ac4c-QGTFTSDYSIALE-K ([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQ;

or

Y-Ac4c-QGTFTSDYSIYLDK-K (19-carboxy-heptadecanoyl-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQ.

21. A compound according to claim 1 wherein the peptide backbone of Formula I has the sequence:

YSQGTFTSDYSKYLD-K (Hexadecanoyl-isoGlu) - KAAHDFVEWLLRA;

Y-Aib-QGTFTSDYSIYLDE-K (Hexadecanoyl-isoGlu) - AAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLDK-K (Hexadecanoyl-isoGlu) - AAHDFVEWLLSAGPSSGAPPPS;

Y-Aib-QGTFTSDYSKYLDK-K (Hexadecanoyl-isoGlu) - AAHDFVEWLLSA;

Y-Aib-QGTFTSDYSIYLEK-K (Hexadecanoyl-isoGlu) - AAKEFVEWLLSA;

-continued

Y-Aib-QGTFTSDYSIYLE-K (Hexadecanoyl-isoGlu) - KAAKEFVEWLLSA;

Y-Aib-QGTFTSDYS-K (Hexadecanoyl-isoGlu) - YLEKKAKEFVEWLLSA;

Y-Aib-QGTFTSDYSIYLEK-K (Hexadecanoyl-isoGlu) - AAKEFVEWLLSAGPSSGAPPPS;

Y-Aib-QGTFTSDYSIYLEK-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AAKEFVEWLLSAGPSSGAPPPS;

Y-Aib-QGTFTSDYSIYLEK-K ([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3) - AAKEFVEWLLSAGPSSGAPPPS;

Y-Aib-QGTFTSDYSIYLDK-K ([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQGPSSGAPPPS;

Y-Aib-QGTFTSDYSIYLDK-K ([17-carboxy-heptadecanoyl]-isoGlu) - AQRAFVEWLLAQGPSSGAPPPS;

Y-Aib-QGTFTSDYSIYLDK-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQGPSSGAPPPS;

Y-Aib-QGTFTSDYSIYLD-K (eicosanoyl-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQGPSSGAPPPS;

Y-Aib-QGTFTSDYSIALEK-K ([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQK;

Y-Aib-QGTFTSDYSIALEK-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQK;

Y-Aib-QGTFTSDYSIALE-K ([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQK;

Y-Aib-QGTFTSDLSIALE-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQK;

Y-Aib-QGTFTSDYSKYLDE-K (Hexadecanoyl-isoGlu) - AAKDFIEWLESA;

Y-Aib-QGTFTSDYSIYLDE-K (Hexadecanoyl-isoGlu) - AAKDFVEWLESA;

Y-Aib-QGTFTSDYSIYLDE-K (Hexadecanoyl-isoGlu) - AAKDFIEWLESA;

Y-Aib-QGTFTSDYSIYLDE-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AAKEFIEWLESA;

Y-Aib-QGTFTSDYSIYLDE-K ([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3) - AAKEFIEWLESA;

Y-Aib-QGTFTSDYSIYLDK-K (Hexadecanoyl-isoGlu) - AAHDFVEWLLRA;

Y-Aib-QGTFTSDYSIYLE-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AQRAFVEWLLRA;

Y-Aib-QGTFTSDYSIYLE-K ([17-carboxy-heptadecanoyl]-isoGlu-Peg3-Peg3) - AQRAFVEWLLRA;

Y-Aib-QGTFTSDYSIALD-K (Octadecanoyl-isoGlu-Peg3-Peg3) - AQRAFNWLVLA-Aib-KPSSGAPPPS;

Y-Aib-QGTFTSDYSIALD-K (Octadecanoyl-Dapa-Peg3-Peg3) - AQRAFNWLVLA-Aib-KPSSGAPPPS;

Y-Aib-QGTFTSDYSIALDK-K ([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3) - AQRAFNWLVLA-Aib-KPSSGAPPPS;

Y-Ac4c-QGTFTSDYSIYLDK-K ([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3) - AAKEFIEWLESA;

Y-Ac4c-QGTFTSDYSIALE-K ([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQK;

-continued

or

Y-Ac4c-QGTFTSDYSIYLDK-K (19-carboxy-heptadecanoyl-isoGlu-Peg3-Peg3) - AQRAFVEWLLAQGPSSGAPPPS

22. A nucleic acid encoding a peptide having the sequence of Formula I.

23. An expression construct comprising a nucleic acid according to claim **22**.

24. A host cell comprising a nucleic acid according to **22** or an expression construct according to claim **23** and capable of expressing, and optionally secreting, the peptide.

25. A pharmaceutical composition comprising a triple agonist compound according to any one of claims **1** to **21**, or a pharmaceutically acceptable salt or solvate thereof, in admixture with a carrier.

26. A pharmaceutical composition according to claim **25** formulated as a liquid suitable for administration by injection or infusion, or formulated to cause slow release of said triple agonist compound.

27. A triple agonist compound according to any one of claims **1** to **21**, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of medical treatment.

28. A triple agonist compound according to any one of claims **1** to **21**, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment and/or prevention of a metabolic disorder.

29. A triple agonist compound for use according to claim **28** wherein the metabolic disorder is diabetes or a diabetes related disorder, or obesity or an obesity related disorder.

30. A triple agonist compound for use according to claim **29** wherein the diabetes related disorder is insulin resistance, glucose intolerance, increased fasting glucose, pre-diabetes, type 1 diabetes, type 2 diabetes, gestational diabetes hypertension, dyslipidemia, bone related disorder or a combination thereof.

31. A GIP analogue or pharmaceutically acceptable salt or solvate thereof for use according to claim **30** wherein the diabetes-related disorder is osteoporosis, including increased risk of bone fracture.

32. A triple agonist compound for use according to claim **29** wherein the diabetes related disorder is atherosclerosis, arteriosclerosis, coronary heart disease, peripheral artery disease, stroke; or is a condition associated with atherogenic dyslipidemia, a blood fat disorder, elevated blood pressure, hypertension, a prothrombotic state, or a proinflammatory state.

33. A triple agonist compound for use according to claim **32** wherein the blood fat disorder is high triglycerides, low HDL cholesterol, high LDL cholesterol, plaque buildup in artery walls, or a combination thereof.

34. A triple agonist compound for use according to claim **32** wherein the prothrombotic state comprises high fibrinogen levels in the blood or high plasminogen activator inhibitor-1 levels in the blood.

35. A triple agonist compound for use according to claim **32** wherein the proinflammatory state comprises an elevated C-reactive protein level in the blood.

36. A triple agonist compound for use according to claim **32** wherein the obesity related disorder is obesity linked inflammation, obesity linked gallbladder disease or obesity induced sleep apnea, or may be associated with a condition selected from atherogenic dyslipidemia, blood fat disorders, elevated blood pressure, hypertension, a prothrombotic state, and a proinflammatory state, or a combination thereof.

* * * * *